Список литературы

Поставить закладку

Sackett D.L., Rosenberg W.M., Gray J.A. et al. Evidence based medicine: what it is and what it isn"t. BMJ 1996, January; 312 (7023): 71–72.
Федеральный закон от 21.11.2011 № 323-ФЗ (ред. от 03.04.2017) "Об основах охраны здоровья граждан в Российской Федерации".
Эпидемиологический словарь, 4-е издание. Под редакцией Джона М. Ласта для Международной эпидемиологической ассоциации. Москва, 2009, 316 стр.
Федеральное агентство по техническому регулированию и метрологии. Национальный стандарт Российской Федерации. ГОСТР 52379-2005. Надлежащая клиническая практика. Москва, 2005.
Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 03.07.2016) «Об обращении лекарственных средств».
Малая медицинская энциклопедия. – М.: Медицинская энциклопедия. 1991–96 гг. [Электронный ресурс]. Режим доступа: http://dic.academic.ru/dic.nsf/enc_medicine/28878/ Синдром
Андреева Н.С., Реброва О.Ю., Зорин Н.А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. – 2012. – №. 4. – С. 10-24.
Eckart R.E., Shry E.A., Burke A.P. et al. Department of Defense Cardiovascular Death Registry G. Sudden death in young adults: an autopsy–based series of a population undergoing active surveillance // J. Am. Coil. Cardiol. – 2011. – Vol. 58. – P. 1254–1261.
Van der Werf C., Hendrix A. et al. Improving usual care after sudden death in the young with focus on inherited cardiac diseases (the CAREFUL study): a community–based intervention study // Europace. – 2015. – Apr 1. – pii: euv059.
United Nations Economic Commission for Europe. UNECE statistical database. Available at http://w3.unece.org/pxweb
Макаров Л.М., Комолятова В.Н., Киселева И.И., Солохин Ю.А. Распространенность внезапной сердечной смерти у лиц молодого возраста в крупном мегаполисе // Медицинский алфавит – 2014. – 3 (Кардиология № 1). – С. 35–40.
Бокерия Л.А., Ревишвили А.Ш., Неминущий Н.М. Внезапная сердечная смерть. – М.:ГЭОТАР-Медиа, 2011. – 267 с.
Myerburg R.J., Kessler K.M., Castellanos A. Sudden cardiac death. Structure, function, and time– dependence of risk // Circulation. – 1992. – Vol. 85. – P. 12–10.
Perk J., De Backer G., Gohlke H. et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) // Eur. Heart J. – 2012. – Vol. 33. – P. 1635–1701.
Jouven X., Desnos M., Guerot C., Ducimetiere P. Predicting sudden death in the population: the Paris Prospective Study I // Circulation. – 1999. – Vol. 99. – P. 1978–1983.
Friedlander Y., Siscovick D.S., Weinmann S. et al. Family history as a risk factor for primary cardiac arrest // Circulation. – 1998. – Vol. 77. – P. 155–160.
Kaikkonen K.S., Kortelainen M.L., Linna E., Huikuri H.V. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event // Circulation. – 2006. – Vol. 114. – P. 1462–1467.
Bezzina C.R., Pazoki R., Bardai A. et al. Genome–wide association study identiﬁes a susceptibility locus at 21q21 for ventricular ﬁbrillation in acute myocardial infarction // Nat. Genet. – 2010. – Vol. 42. – P. 688–691.
Dekker L.R., Bezzina C.R., Henriques J.P. et al. Familial sudden death is an important risk factor for primary ventricular ﬁbrillation: a case-control study in acute myocardial infarction patients // Circulation. – 2006. – Vol. 114. – P. 1140–1145.
Yoshinaga M., Kucho Y., Sarantuya J. et al. Genetic characteristics of children and adults with long QT syndrome diagnosed by school-based electrocardiographic screening programs // Circ. Arrhythm. Electrophysiol. – 2014. – Vol. 7. – P. 107–112.
Schwartz P.J., Stramba–Badiate M., Crotti L. et al. Prevalence of the congenital long QT syndrome // Circulation. – 2009. – Vol. 120. – P. 1761–1767.
Corrado D., Petticcia A., Bjornstad H.H. et al. Cardiovascular pre–participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology // Eur. Heart J. – 2005. – Vol. 26. – P. 516–524.
Maron B.J., Thompson P.D., Ackerman M.J. et al. Recommendations and considerations related to preparticipation screening for cardiovascutar abnormalities in competitive athletes: 2007 update: a scientiﬁc statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation // Circulation. – 2007. – Vol. 115. – P. 1643–1455.
Ljungqvist A., Jenoure P., Engebretsen L. et al. The International Olympic Committee (IOC) consensus statement on periodic health evaluation of elite athletes, March 2009 // Br. J. Sports Meal. – 2009. – Vol. 43. – P. 631–643.
Steinvil A., Chundadze T., Zeltser D. et al. Mandatory etectrocardiographic screening of athletes to reduce their risk for sudden death: proven fact or wishful thinking? // J. Am. Coll. Cardiol. – 2011. – Vol. 57. – P. 1291–1296.
Zipes D.P., Camm A.J., Borggrefe M. et al. ACC/AHA/ЕОК 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. – Circulation – 2006. – v. 114 – p. e385-e484.
Priori S.G., Blomström-Lundqvist C., Mazzanti A. et al. 2015 ЕОК Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology. – Eur Heart J. – 2015. – 36(41). – p. 2793–867.
Piepoli M.F., Hoes A.W., Agewall S., et al; Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37:2315–2381. doi:10.1093/eurheartj/ehw106.
Casella M., Carbucicchio C., Russo E., et al. Electrical storm in systemic sclerosis: Inside the electroanatomic substrate. World J Cardiol. 2014; 6(10): 1127–1130. doi:10.4330/ wjc.v6.i10.1127.
Dechering D.G., Kochhauser S., Wasmer K. et al. Electrophysiological characteristics of ventricular tachyarrhythmias in cardiac sarcoidosis versus arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2013; 10:158-164.
Cardinalti-Neto A., Bestetti R.B., Cordeiro J.A., Rodrigues V.C. Predictors of all-cause mortality for patients with chronic Chagas" heart disease receiving implantable cardioverter deﬁbrillator therapy. J. Cardiovasc Electrophysiol 2007; 18:1236-1240.
Scheffold N., Herkommer B., Kandolf R., May A.E. Lyme carditis diagnosis, treatment and prognosis. Dtsch Arztebl Int. 2015;112(12):202–208. doi:10.3238/arztebl.2015.0202
Apshtein A.E., Ideker R.E. Ventricular Fibrillation in “Cardiac Electrophysiology. From Cell to Bedside”, ed. By Zipes D.P. and Jalife J., W.B. Saunders Company – 2000 – p. 677-684.
Epstein A.E., Dimarco J.P., Ellenbogen K.A. et al. ACC/AHA/HRS 2008 Guidelines for Device- Based Therapy of Cardiac Rhythm Abnormalities – Circulation – 2008 –v. 117 – p. e450–e408.
George S., Rodriguez I., Ipe D., Sager P.T., Gussak I., Vajdic B. Computerized extraction of electrocardiograms from continuous 12-lead Holter recordings reduces measurement variability in a thorough QT study. J. Clin Pharmacol 2012;52: 1891-1900.
Volosin K., Stadler R.W., Wyszynski R., Kirchhof P. Tachycardia detection performance of implantable Loop recorders: results from a large "real-life" patient cohort and patients with induced ventricular arrhythmias. Europace 2013; 15:1215-1222.
de Asmundis C., Conte G., Sieira J., Chierchia G.B., Rodriguez-Manero M., Di Giovanni G., Ciconte G., Levinstein M., Baltogiannis G., Saitoh Y., Casado-Arroyo R., Brugada P. Comparison of the patient-activated event recording system vs. traditional 24 h Holter electrocardiography in individuals with paroxysmal palpitations or dizziness. Europace 2014; 16:1231-1235.
Kamath G.S., Zareba W., Delaney J., Koneru J.N., McKenna W., Gear K., Polonsky S., Sherri U.D., Bluemke D., Marcus F., Steinberg J.S. Value of the signal-averaged electrocardiogram in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm 2011; 8:256-262.
Nava A., Folino A.F., Bauce B., Turrini P., Buja G.F., Daliento L., Thiene G. Signal-averaged electrocardiogram in patients with arrhythmogenic right ventricular cardiomyopathy and ventricular arrhythmias. Eur HeartJ 2000; 21:58-65.
Cheitlin M.D., Armstrong W.F., Aurigemma G.P., Beller G.A., Bierman F.Z., Davis J.L., Douglas P.S., Faxon D.P., Gi Uam L.D., Kimball T.R., Kussmaul W.G., Pearlman A.S., Philbrick J.T., Rakowski H., Thys D.M. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography – summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J. Am CoU Cardiol 2003;42: 954-970.
Prastaro M., D"Amore C., Paolillo S., Losi M., Marciano C., Perrino C., Ruggiero D., Gargiulo P., Savarese G., Trimarco B., Perrone Filardi P. Prognostic role of transthoracic echocardiography in patients affected by heart failure and reduced ejection fraction. Heart Fail Rev 2015; 28:305-316.
Chiu D.T., Shapiro N.I., Sun B.C., Mottley J.L., Grossman S.A. Are echocardiography, telemetry, ambulatory electrocardiography monitoring, and cardiac enzymes in emergency department patients presenting with syncope useful tests? A preliminary investigation. J. Emerg Med 2014; 47:113 – 118.
Zellweger M.J., Hachamovitch R., Kang X., Hayes S.W., Friedman J.D., Germano G., Berman D.S. Threshold, incidence, and predictors of prognostically high-risk silent ischemia in asymptomatic patients without prior diagnosis of coronary artery disease. J. Nud Cardiol 2009; 16:193 – 200.
Podrid P.J., Graboys T.B. Exercise stress testing in the management of cardiac rhythm disorders. Med Clin North Am 1984; 68:1139 – 1152.
Kang X., Berman D.S., Lewin H., Miranda R., Erel J., Friedman J.D., Amanullah A.M. Comparative ability of myocardial perfusion single-photon emission computed tomography to detect coronary artery disease in patients with and without diabetes mellitus. Am HeartJ 1999; 137:949-957.
Zelias A., Stepinska J., Andres J., Trabka-Zawicki A., Sadowski J., Zmudka K. Ten-year experience of an invasive cardiology centre with out-of-hospital cardiac arrest patients admitted for urgent coronary angiography. Kardiol Pol 2014; 72:687-699.
Zaman S., Narayan A., Thiagalingam A., Sivagangabalan G., Thomas S., Ross D.L., Kovoor P. Signiﬁcance of repeat programmed ventricular stimulation at electrophysiology study for arrhythmia prediction after acute myocardial infarction. Pacing Clin Electrophysiol 2014; 37:795-802.
Denes P., Uretz E., Ezri M.D., Borbola J. Clinical predictors of electrophysiologic ﬁndings in patients with syncope of unknown origin. Arch Intern Med 1988; 148: 1922-1928.
Brignole M., Menozzi C., Moya A., Garcia-Civera R., Mont L., Alvarez M., Errazquin F., Beiras J., Bottoni N., Donateo P. International Study on Syncope of Uncertain Etiology (ISSUE) Investigators. Mechanism of syncope in patients with bundle branch block and negative electrophysiological test. Circulation 2001; 104:2045-2050.
Brembilla-Perrot B., Suty-Selton C., Houriez P., Claudon O., Beurrier D., de la Chaise A.T. Value of non-invasive and invasive studies in patients with bundle branch block, syncope and history of myocardial infarction. Europace 2001; 3: 187-194.
Ackerman M.J., Priori S.G., Willems S. et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). – Heart Rhythm. – 2011. – 8(8). – p. 1308–39.
Basso C., Burke M., Fornes P., Gattagher P.J., de Gouveia R.H., Sheppard M., Thiene G., van der Wal A. Association for European Cardiovascular P. Guidelines for autopsy investigation of sudden cardiac death. Virchows Arch 2008; 452:11-18.
Basso C., Carturan E., Pilichou K., Rizzo S., Corrado D., Thiene G. Sudden cardiac death with normal heart: molecular autopsy. Cardiovasc Pathol 2010; 19:321-325.
Tester D.J., Medeiros-Domingo A., Will M.L., Haglund C.M., Ackerman M.J. Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsynegative sudden unexplained death referred for postmortem genetic testing. Mayo Clin Proc 2012; 87:524-539.
Windecker S., Koth P., Alfonso F. et al. 2014 ЕОК/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ЕОК) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014; 35:2541-2619.
Rofﬁ M., Patrono C., Cotter J.P. et al. 2015 ЕОК Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. Eur Heart J. 2015. doi:10.1093/eurheartj/ehv320.
Steg P.G., James S.K., Atar D. et al. ЕОК Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33:2569-2619.
Hohnloser S.H., Kuck K.H., Dorian P. et al. Investigators D. Prophylactic use of an implantable cardioverter-deﬁbrillator after acute myocardial infarction. N Engl J. Med. 2004; 351:2481-2488.
Spaulding C.M., Joly L.M., Rosenberg A. et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J. Med. 1997; 336:1629-1633.
Dumas F., Cariou A., Manzo-Sitberman S. et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv 2010; 3:200- 207.
Noc M., Fajadet J., Lassen J.F. et al. Invasive coronary treatment strategies for out-of-hospital cardiac arrest: a consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups. Eurointervention 2014; 10:31- 37.
Al-Khatib S.M., Stevenson W.G., Ackerman M.J. et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the HeartRhythm Society. J. Am Coll Cardiol. 2018 Oct 2; 72(14):1677-1749.
Irvine J., Dorian P., Baker B. et al. Quality of life in the Canadian Implantable Deﬁbrillator Study (CIDS). Am Heart J. 2002; 144:282-289.
Weisfeldt M.L., Sitlani C.M., Ornato J.P. et al. Survival after application of automatic external deﬁbrillators before arrival of the emergency medical system: evaluation in the resuscitation outcomes consortium population of 21 million. J. Am Coil Cardiol 2010; 55:1713-1720.
Nolan J.P., Soar J., Zideman D.A. et al. Group ERCGW. European Resuscitation Council Guidelines for Resuscitation 2010 Section 1. Executive summary. Resuscitation 2010; 81: 1219- 1276.
Soholm H., Wachte U.K., Nietsen S.L. et al. Tertiary centres have improved survival compared to other hospitals in the Copenhagen area after out-of-hospital cardiac arrest // Resuscitation. – 2013. – Vol. 84. – P. 162–167.
Xiao G., Guo Q., Shu M. et al. Safety proﬁle and outcome of mild therapeutic hypothermia in patients following cardiac arrest: systematic review and meta–analysis // Emerg. Med. J. – 2013. – Vol. 30. – P. 91–100.
Boersma E., Maas A.C., Deckers J.W., Simoons M.L. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour // Lancet.– 1996. – Vol. 348. – P. 771–775.
Boersma E. Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital ﬁbrinolysis in acute myocardial infarction patients // Eur. Heart J. – 2006. – Vol. 27. – P. 779–788.
Keeley E.C., Boura J.A., Grines C.L. Comparison of primary and facilitated percutaneous coronary interventions for ST-etevation myocardial infarction: quantitative review of randomised trials // Lancet. – 2006. – Vol. 367. – P. 579–588.
Bowers T.R., O"Neitt W.W., Grines C. et al. Effect of reperfusion on biventricular function and survival after right ventricular infarction. N Engl J. Med 1998; 338:933-940.
Gorenek B., Blomstrom Lundqvist C., Brugada P., Terradetlas J. et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EH RA, ACCA, and EAPCI task force. Europace 2014; 16:1655-1673.
Piccini J.P., Hranitzky P.M., Kilaru R. et al. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular ﬁbrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). Am J Cardiol 2008; 102:1427-1432.
Huikuri H.V., Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J. Med. 2001; 345:1473-1482.
Bougouin W., Marijon E., Puymirat E. et al. Incidence of sudden cardiac death after ventricular ﬁbrillation complicating acute myocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 registry. Eur Heart J. 2014; 35:116-122.
Buxton A.E., Lee K.L., DiCarlo L. et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J. Med. 2000; 342: 1937-1945.
Buxton A.E., Lee K.L., Harley G.E. et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J. Am Coil Cardiol 2007; 50:1150-1157.
Gatzoutis K.A., Tsiachris D., Arsenos P. et al. Prognostic value of programmed ventricular stimulation for sudden death in selected high risk patients with structural heart disease and preserved systolic function. Int J. Cardiol 2014; 176: 1449-1451.
Exner D.V., Kavanagh K.M., Stawnych M.P. et al. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J. Am Coil Cardiol 2007; 50:2275-2284.
Malik M., Camm A.J., Janse M.J. et al. Depressed heart rate variability identiﬁes postinfarction patients who might beneﬁt from prophylactic treatment with amiodarone: a substudy of EMIAT (the European Myocardial Infarct Amiodarone Triat). J. Am Coil Cardiol 2000; 35:1263-1275.
Auman K.C., Shaw L.J., Hachamovitch R., Udelson J.E. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J. Am Coil Cardiol 2002; 39: 1151-1158.
Steinbeck G., Andresen D., Seidl K. et al. IRIS Investigators. Deﬁbrillator implantation early after myocardial infarction. N Engl J. Med. 2009; 361:1427-1436.
Kelly P., Ruskin J.N., VTahakes G.J. et al. Surgical coronary revascularization in survivors of prehospital cardiac arrest: its effect on inducible ventricular arrhythmias and long-term survival. J .Am Coil Cardio1. 1990; 15: 267-273.
van der Burg A.E., Bax J.J., Boersma E. et al. Impact of viability, ischemia, scar tissue, and revascularization on outcome after aborted sudden death. Circulation 2003; 108:1954-1959.
Al Jaroudi W.A., Refaat M.M., Habib R.H. et al. Genetic Risk Assessment of Deﬁbrillator Events Investigators. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac deﬁbrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study). Am J Cardiol 2015; 115:924-931.
Pitt B., White H., Nicolau J. et al. EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J. Am Coil Cardiol 2005; 46:425-431.
Peck K.Y., Lim Y.Z., Horofﬁpper I., Krum H. Medical therapy versus implantable cardioverter- deﬁbrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of >35,000 patients. Int J. Cardiol 2014; 173:197- 203.
Chatterjee S., Udetl J.A., Sardar P. et al. Comparable beneﬁt of betablocker therapy in heart failure across regions of the world: meta-analysis of randomized clinical trials. Can J. Cardiol 2014; 30:898-903.
Neumann F., Sousa-Uva M., Ahlsson A. et al. 2018 ЕОК/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019; 40(2):87-165.
Dor V., Civaia F., Alexandrescu C., Sabatier M., Montiglio F. Favorable effects of left ventricular reconstruction in patients excluded from the Surgical Treatments for Ischemic Heart Failure (STICH) trial. J. Thorac Cardiovasc Surg. 2011; 141:905-16. doi.org/10.1016/j.jtcvs.2010.10.026.
Jones R.H., Ve-lazquez E.J., Michler R.E., et al. STICH Hy-pothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. New England Journal of Medicine. 2009;360(17):1705–17.
Nguyen K.T., Vittinghoff E., Dewland T.A. et al. Ectopy on a Single 12-Lead ECG, Incident Cardiac Myopathy, and Death in the Community. J. Am Heart Assoc. 2017; 6. pii: e006028. doi: 10.1161/JAHA.117.006028.
Dukes J.W., Dewland T.A., Vittinghoff E. et al. Ectopy as a Predictor of Heart Failure and Death. J. Am Coll Cardiol. 2015; 66:101-109. doi: 10.1016/j.jacc.2015.04.062.
Shimizu W. Arrhythmias originating from the right ventricular outﬂow tract: how to distinguish “malignant” from “benign”? HeartRhythm, 2009; 6:15071511.
Jamil H.A., Mohammed S.A., Gierula J. et al. Signiﬁcance of Incidental Nonsustained Ventricular Tachycardia Detected on Pacemaker Interrogation. Am J. Cardiol., 2019; 123: 409-413. https://doi.org/10.1016/j.amjcard.2018.10.040.
Dabbagh G.S., Bogun F. Predictors and therapy of cardiomyopathy caused by frequent ventricular ectopy. Curr Cardiol Rep, 2017; 19: 80.
Hyman M.C., Mustin D., Supple G. et al. Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy. Heart Rhythm, 2018; 15: 159-163.
Ling Z., Liu Z., Su L. et al. Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outﬂow tract: prospective randomized study. Circ Arrhythm Electrophysiol, 2014; 7: 237-243.
Goy J.J., Tauxe F., Fromer M., Schläpfer J., Vogt P., Kappenberger L. Ten-years follow-up of 20 patients with idiopathic ventricular tachycardia. Pacing Clin Electrophysiol. 1990; 13:1142-1147.
Mont L., Seixas T., Brugada P., Brugada J., Simonis F., Rodríguez L.M., Smeets J.L., Wellens H.J. Clinical and electrophysiologic characteristics of exercise-related idiopathic ventricular tachycardia. Am J. Cardiol. 1991; 68:897-900.
Toivonen L., Nieminen M. Persistent ventricular tachycardia resulting in left ventricular dilatation treated with verapamil. Int J. Cardiol. 1986; 13:361-365.
Singh B., Kaul U., Talwar K.K., Wasir H.S. Reversibility of tachycardia induced cardiomyopathy following the cure of idiopathic left ventricular tachycardia using radiofrequency energy. Pacing Clin Electrophysiol. 1996; 19:1391–1392.
Prystowsky E.N., Padanilam B.J., Joshi S., Fogel R.I. Ventricular Arrhythmias in the Absence of Structural Heart Disease. JACC, 2012; 59:1733-1744. https://doi.org/10.1016/j.jacc.2012.01.036.
Lerman B. Ventricular tachycardia in patients with structurally normal hearts. D.P. Zipes, J. Jalife (Eds.). Cardiac Electrophysiology: From Cell to Bedside (5th ed.), WB Saunders, Philadelphia, PA, 2009, 657-667]. Pacing Clin Electrophysiol. 1996; 19:1391–1392.
Ruberman W., Weinblatt E., Goldberg J.D. et al. Ventricular premature beats and mortality after myocardial infarction. N Eng J. Med. 1977; 297:750–757.
Engstrom G., Hedblad B., Janzon L. et al. Ventricular Arrhythmias during 24 hour ambulatory ECG recording: incidence, risk factors and prognosis in men with and without a history of cardiovascular disease. J. Intern Med. 1999; 246:363–372.
Hoffmann A., Buhler F.R., Burckhardt D. High-grade ventricular ectopic activity and 5 year survival in patients with chronic heart disease and in healthy subjects. Cardiology 1983; 70(S1):82–87.
Bikkina M., Larson M.G., Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J. Am Coll Cardiol. 1993; 22:1111–1116.
Adabag A.S., Casey S.A., Kuskowski M.A. et al. Spectrum and prognostic signiﬁcance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J. Am Coll Cardiol, 2005; 45: 697-704.
Freemantle N., Cleland J., Young P. et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318:1730–1737.
Al-Gobari M., El Khatib C., Pillon F., Gueyfﬁer F. β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2013; 13:52. doi: 10.1186/1471-2261-13-52.
Cleophas T.J., Zwinderman A.H. Beta-blockers and heart failure: meta-analysis of mortality trials. Int J. Clin Pharmacol Ther. 2001; 39:383-388.
Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J. Cardiol. 1997; 80:35J-39J.
Fisher F.D., Tyroler H.A. Relationship between ventricular premature contractions on routine electrocardiography and subsequent sudden death from coronary heart disease. Circulation 1973; 47:712–19.
Al-Gobari M., Al-Aqeel S., Gueyfﬁer F., Burnand B. Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews. BMJ Open. 2018; 8:e021108. doi: 10.1136/bmjopen-2017- 021108.
Ahn J., Kim H.J., Choi J.I. et al. Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: A meta-analysis. PLoS One. 2017 Oct 23; 12(10):e0185680. doi: 10.1371/journal.pone.0185680. eCollection 2017.
Echt D.S., Liebson P.R., Mitchell L.B. et al. Mortality and morbidity in patients receiving encainide, ﬂecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J. Med., 1991; 324: 781-788. https://doi.org/10.1056/NEJM199103213241201.
Cardiac Arrhythmia Suppression Trial (CAST) II Investigators. Effect of antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J. Med. 1992; 327:227–33.
Ho A.T., Pai S.M., Timothy P., Pai R.G. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter deﬁbrillators. Pacing Clin Electrophysiol. 2005; 28:647-653.
Latchamsetty R., Bogun F. Premature Ventricular Complexes and Premature Ventricular Complex Induced Cardiomyopathy. Curr Probl Cardiol. 2015; 40:379-422. doi: 10.1016/j.cpcardiol.2015.03.002.
Baman T.S., Lange D.C., Ilg K. et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010; 7:865–859.
Hayes D.L., Boehmer J.P., Day J.D. et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm, 2011; 8:1469-1475.
Koplan A., Kaplan A.J., Weiner S., Jones P.W., Seth M., Christman S.A. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J. Am Coll Cardiol, 2009; 53:355-360.
Ruwald M.H., Solomon S.D., Foster E., Kutyifa V., Ruwald A.C., Sherazi S. et al. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Deﬁbrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation, 2014; 130:2278-2286.
Julian D., Camm A., Frangin G. et al. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349:667–74.
Cairns J., Connolly S., Roberts R. et al. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997; 349:675–82.
Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., Domanski M., Troutman C., Anderson J., Johnson G., McNulty S.E., Clapp-Channing N., Davidson-Ray L.D., Fraulo E.S., Fishbein D.P., Luceri R.M., Ip J.H. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-deﬁbrillator for congestive heart failure. N Engl J. Med. 2005; 352:225–237.
Vorperian V.R., Havighurst T.C., Miller S., January C.T. Adverse effects of low dose amiodarone: a meta-analysis. J. Am Coll Cardiol. 1997; 30:791–798.
Kuck K.H., Cappato R., Siebels J., Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable deﬁbrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000; 102:748-754.
Furberg C.D., Yusuf S. Effect of drug therapy on survival in chronic congestive heart failure. Am. J. Cardiol., 1988; 62:41A-45A.
Mahe I., Chassany O., Grenard A.S., Caulin C., Bergmann J.F. Deﬁning the role of calcium channel antagonists in heart failure due to systolic dysfunction. Am. J. Cardiovasc. Drugs, 2003; 3: 33-41.
Masarone, Limongelli G., Rubino M., Valente F., Vastarella R., Ammendola E., Gravino R., Verrengia M., Salerno G., Pacileo G. Management of Arrhythmias in Heart Failure J. Cardiovasc. Dev. Dis., 2017; 4: 3 https://doi.org/10.3390/jcdd4010003.
Podrid P., Lown B. Selection of an antiarrhythmic drug to protect against ventricular ﬁbrillation. In Proceedings of the ﬁrst US-USSR Symposium on Sudden Death. DHEW publ. no. (NIH) 78- 1470, 1978; pp 259-278.
Mason J.W. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med. 1993; 329:452-458.
Connolly S.J., Dorian P., Roberts R.S., Gent M., Bailin S., Fain E.S. et al. Comparison of beta- blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter deﬁbrillators: the OPTIC Study: a randomized trial. JAMA, 2006, 295:165-171.
Paciﬁco A., Hohnloser S.H., Williams J.H., Tao B., Saksena S., Henry P.D. et al. Prevention of implantable-deﬁbrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter- Deﬁbrillator Study Group. N Engl J. Med. 1999; 340: 1855-1862. https://doi.org/10.1056/NEJM199906173402402.
Picini J.P. et al. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009; 30:1245-1253. doi:10.1093/eurheartj/ehp1.
Connolly S.J., Hallstrom A.P., Cappato R., Schron E.B., Kuck K.H., Zipes D.P. et al. Meta-analysis of the implantable cardioverter deﬁbrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Deﬁbrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Deﬁbrillator Study. Eur Heart J. 2000; 21:2071–2078.
Sroubek Jakub, Buxton Alfred E. Primary Prevention Implantable Cardiac Deﬁbrillator Trials: What Have We Learned? Card Electrophysiol Clin. 2017 Dec;9(4):761-773. doi: 10.1016/j.ccep.2017.08.006.
Aiba T., Kurita T., Taguchi A., Shimizu W., Suyama K., Aihara N., Kamakura S. Long-term efﬁcacy of empirical chronic amiodarone therapy in patients with sustained ventricular tachyarrhythmia and structural heart disease. Circ J. 2002; 66:367-71.
Bokhari F., Newman D., Greene M., Korley V., Mangat I., Dorian P. Long-term comparison of the implantable cardioverter deﬁbrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Deﬁbrillator Study (CIDS). Circulation. 2004; 110:112– 116.
Yager N, Wang K, Keshwani N, Torosoff M. Phenytoin as an effective treatment for polymorphic ventricular tachycardia due to QT prolongation in a patient with multiple drug intolerances. BMJ Case Rep 2015;2015:bcr2015209521. doi:10.1136/bcr-2015-209521
Abdel Wahab A., Sapp J. Ventricular tachycardia with ICD shocks: when to medicate and when to ablate. Curr Cardiol Rep, 2017; 19:105.
Sapp J.L., Wells G.A., Parkash R., Stevenson W.G., Blier L., Sarrazin J.F. et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J. Med. 2016; 375:111– 121. https://doi.org/10.1056/NEJMoa1513614.
Deyell M.W., Steinberg C., Doucette S., Parkash R., Nault I., Gray C., Essebag V., Gardner M., Sterns L.D., Healey J.S., Hruczkowski T., Rivard L., Leong-Sit P., Nery P.B., Sapp J.L. Mexiletine or catheter ablation after amiodarone failure in the VANISH trial. J Cardiovasc Electrophysiol. 2018; 29:603-608. doi: 10.1111/jce.13431.
Gao D., Van Herendael H., Alshengeiti L., Dorian P., Mangat I., Korley V., Ahmad K., Golovchiner G., Aves T., Pinter A. Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable deﬁbrillator. J. Cardiovasc Pharmacol. 2013 Aug; 62(2):199-204. doi: 10.1097/FJC.0b013e31829651fe.
El-Sherif N., Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J. 2011; 18:233-245.
Veenhuyzen G.D., Wyse D.G. Life threatening ventricular arrhythmias with transient or correctable causes. Minerva Cardioangiol. 2003; 51:275-286.
Wyse D.G., Friedman P.L., Brodsky M.A., Beckman K.J., Carlson M.D., Curtis A.B., Hallstrom A.P., Raitt M.H., Wilkoff B.L., Greene H.L. AVID Investigators. Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol. 2001; 38:1718-1724.
Link M.S., Berkow L.C., Kudenchuk P.J. et al. Part 7: adult advanced cardiovascular life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015; 132 (suppl 2): S444-64.
Stiell I.G., Wells G.A., Field B. et al. Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med. 2004; 351:647-56.
Sasson C., Rogers M.A., Dahl J. et al. Predictors of survival from out-of-hospital cardiac arrest: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2010; 3:63-81.
Fogoros RN, Fiedler SB, Elson JJ. Efﬁcacy of phenytoin in suppressing inducible ventricular tachyarrhythmias. Cardiovasc Drugs Ther. 1988;2(2):171-6. doi: 10.1007/BF00051232.PMID: 3154703.
Dorian P., Cass D., Schwartz B. et al. Amiodarone as compared with lidocaine for shock-resistant ventricular ﬁbrillation. N Engl J Med. 2002; 346:884-90.
Kudenchuk P.J., Brown S.P., Daya M. et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016; 1711-22.
Kudenchuk P.J., Cobb L.A., Copass M.K. et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular ﬁbrillation. N Engl J Med. 1999; 341:871-8.
Herlitz J., Ekstrom L., Wennerblom B. et al. Lidocaine in out-of-hospital ventricular ﬁbrillation. Does it improve survival? Resuscitation. 1997; 33:199-205.
Kudenchuk P.J., Newell C., White L. et al. Prophylactic lidocaine for post resuscitation care of patients with out-ofhospital ventricular ﬁbrillation cardiac arrest. Resuscitation. 2013; 84:1512- 8.
Callaham M., Madsen C.D., Barton C.W. et al. A randomized clinical trial of high-dose epinephrine and norepinephrine vs standard-dose epinephrine in prehospital cardiac arrest. JAMA. 1992; 268:2667-72.
Gueugniaud P.Y., Mols P., Goldstein P. et al. A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital. European Epinephrine Study Group. N Engl J Med. 1998;339:1595-601.
Hagihara A., Hasegawa M., Abe T. et al. Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest. JAMA. 2012;307:1161-8.
Best Clinical Practice: Emergency Medicine Management of Stable Monomorphic Ventricular Tachycardia. Long B., Koyfman A. J Emerg Med. 2017 Apr; 52(4):484-492. doi: 10.1016/j.jemermed.2016.09.010. Epub 2016 Oct 15.
Team Management of the Ventricular Tachycardia Patient. Tang P.T., Do D.H., Li A., Boyle N.G. Arrhythmia & Electrophysiology Review 2018; 7(4):238–46. DOI https://doi.org/10.15420/aer.2018.37.2.
Stable tachycardia with wide QRS complex in pre-hospital emergency medicine. Ohlow MA1, Beierlein A., Müller S., von Korn H., Geller J.C., Yu J., Lauer B. Dtsch Med Wochenschr. 2005 Nov 25; 130(47):2694-8 [Article in German].
Cobb L.A., Fahrenbruch C.E., Walsh T.R. et al. Inﬂuence of cardiopulmonary resuscitation prior to deﬁbrillation in patients with out-of-hospital ventricular ﬁbrillation. JAMA. 1999; 281:1182- 8.
Cobb L.A., Weaver W.D., Fahrenbruch C.E. et al. Community-based interventions for sudden cardiac death. Impact, limitations, and changes. Circulation. 1992; 85(suppl):I98-102.
Weisfeldt M.L., Becker L.B. Resuscitation after cardiac arrest: a 3-phase time-sensitive model. JAMA. 2002; 288:3035-8.
Wik L., Hansen T.B., Fylling F. et al. Delaying deﬁbrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ventricular ﬁbrillation: a randomized trial. JAMA. 2003; 289:1389-95.
Eckardt L., Breithardt G., Kirchhof P. Approach to wide complex tachycardias in patients without structural heart disease. Heart. 2006 May; 92(5): 704–711. doi: 10.1136/hrt.2005.063792.
Hudson K.B., Brady W.J., Chan T.C., Pollack M., Harrigan R.A. Electrocardiographic manifestations: ventricular tachycardia. J Emerg Med. 2003 Oct; 25(3):303-14.
Miller J.M., Das M.K., Yadav A.V., Bhakta D., Nair G., Alberte C. Value of the 12-lead ECG in wide QRS tachycardia. Cardiol Clin. 2006 Aug; 24(3):439-51, ix-x.
Goldberger Z.D., Rho R.W., Page R.L. Approach to the diagnosis and initial management of the stable adult patient with a wide complex tachycardia. Am J Cardiol. 2008 May 15; 101(10):1456- 66. doi: 10.1016/j.amjcard.2008.01.024. Epub 2008 Mar 21.
Gorgels A.P., van den Dool A., Hofs A. et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol. 1996; 78:43-6.
Markel D.T., Gold L.S., Allen J. et al. Procainamide and survival in ventricular ﬁbrillation out-of- hospital cardiac arrest. Acad Emerg Med. 2010; 17:617-23.
Ortiz M., Martin A., Arribas F. et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017; 38:1329-35.
Kudenchuk P.J., Brown S.P., Daya M. et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016; 1711-22.
Ho D.S., Zecchin R.P., Richards D.A. et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet. 1994; 344:18-23.
Somberg J.C., Bailin S.J., Haffajee C.I. et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol 2002; 90:853-9.
Teo K.K., Yusuf S., Furberg C.D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA. 1993; 270:1589-95.
Nademanee K., Taylor R., Bailey W.E. et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation. 2000; 102:742-7
Belhassen B., Horowitz L.N. Use of intravenous verapamil for ventricular tachycardia. Am J Cardiol. 1984; 54:1131 -3.
Grifﬁth M.J., Garratt C.J., Rowland E.,Ward D.E., Camm A.J. Effects of intravenous adenosine on verapamil-sensitive “idiopathic” ventricular tachycardia. Am J Cardiol 1994; 73:759–764.
Nogami A., Naito S., Tada H. et al. Demonstration of diastolic and presystolic Purkinje potentials as critical potentials in a macroreentry circuit of verapamil-sensitive idiopathic left ventricular tachycardia. J Am Coll Cardiol. 2000; 36:811 23.
Belhassen B., Rotmensch H.H., Laniado S. Response of recurrent sustained ventricular tachycardia to verapamil. Br Heart J. 1981; 46:679-82.
German L.D., Packer D.L., Bardy G.H. et al. Ventricular tachycardia induced by atrial stimulation in patients without symptomatic cardiac disease. Am J Cardiol. 1983; 52:1202-7.
Tsuchiya T., Okumura K., Honda T. et al. Effects of verapamil and lidocaine on two components of the re-entry circuit of verapamil-senstitive idiopathic left ventricular tachycardia. J Am Coll Cardiol. 2001; 37:1415-21.
Nogami A. Idiopathic left ventricular tachycardia: assessment and treatment. Card Electrophysiol Rev. 2002 Dec; 6(4):448-57.
Diker E., Tezcan K., Ozdemir M., Göksel S. Adenosine sensitive left ventricular tachycardia. Pacing Clin Electrophysiol. 1998 Jan; 21(1 Pt 1):134-6.
Kontos M.C., Diercks D.B., Ho P.M. et al. Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: results from the American College of Cardiology"s NCDR . Am Heart J 2011; 161:864-870.
Chatterjee S., Chaudhuri D., Vedanthan R. et al. Early intravenous betablockers in patients with acute coronary syndrome--a meta-analysis of randomized triats. IntJ Cardiol 2013; 168:915-921.
Bangalore S., Makani H., Radford M. et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-anatysis of randomized trials. Am J Med 2014; 127:939-953.
McMurray J.J., Adamopoutos S., Anker S.D. et al. ЕОК Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ЕОК Eur Heart J 2012;33:1787-1847.
Wotfe C.L., Nibley C., Bhandari A. et al. Polymorphous ventricutar tachycardia associated with acute myocardial infarction. Circulation 1991; 84:1543 – 1551.
Monsieurs K.G., Nolan J.P., Bossaert L.L. et al. European Resuscitation Council Guidelines for Resuscitation 2015 Section 1. Executive summary. Resuscitation 2015; 95:1–80.
Piccini J.P., Schulte P.J., Pieper K.S. et al. Antiarrhythmic drug therapy for sustained ventricutar arrhythmias compticating acute myocardial infarction. Crit Care Med 2011; 39:78-83.
Zafari A.M., Zarter S.K., Heggen V. et al. A program encouraging early deﬁbrillation results in improved inhospital resuscitation efﬁcacy. J Am Coil Cardiol 2004; 44:846-852.
Umeda M., Morimoto A., Yokoyama K. et al. Despite medication, overdrive pacing is required to stabilize the electrical storm associated with acute coronary syndrome: a case report. J Cardiol. 2007 Oct; 50(4):263-9.
Josephson M.E., Almendral J., Callans D.J. Resetting and entrainment of reentrant ventricular tachycardia associated with myocardial infarction. Heart Rhythm. 2014 Jul; 11(7):1239-49.
Yoshida T., Naito Y., Nishimura K. Temporary ventricular overdrive pacing for electrical storm after coronary artery bypass grafting. Gen Thorac Cardiovasc Surg. 2011 Nov; 59(11):756-9.
Chia P.L., Loh S.Y., Foo D. Ventricular tachycardia storm: a case series and literature review. Med J Malaysia. 2012 Dec; 67(6):582-4.
Reddy Y.M., Chinitz L., Mansour I. et al. Percutaneous left ventricular assist devices in ventricutar tachycardia ablation: mutticenter experience. Circ Arrhythm Electrophysio1 2014; 7: 244- 250.
Dor V., Sabatier M., Montiglio F., Rossi P., Toso A., Di Donato M. Results of nonguided subtotal endocardiectomy associated with left ventricular reconstruction in patients with ischemic ventricular arrhythmias // Journal of Thoracic and Cardiovascular Surgery. 1994. Vol. 107(5). P. 1301–1307.
Babokin V., Shipulin V., Batalov R., Popov S. Surgical ventricular reconstruction with endocardectomy along radiofrequency ablation-induced markings // Journal of Thoracic and Cardiovascular Surgery. 2013. Vol. 146(5). P. 1133–1138.
Sartipy U., Albage A., Insulander P., Lindblom D. Surgery for ventricular tachycardia in patients undergoing surgical ventricular restoration: the Karolinska approach // J. Interv. Card. Electrophysiol. – 2007. – Vol. 19. – P. 171–178.
Ревишвили А.Ш. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Москва: Новое издательство, 2017 р. 702. ISBN 978-5-9500922-0-6.
Bayes de Luna A., Coumel P., Leclerq J.F. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases // Am. Heart J.- 1989.-Vol.117- P. 151 – 159.
Josephson M.E., Harken A.H., Horowitz L.N. Endocardial excision: a new surgical technique for the treatment of recurrent ventricular tachycardia // Circulation. – 1979. – Vol. 60. – P. 1430– 1439.
Krishnan S.C., Josephson M.E. Surgery for postinfarction ventricular tachycardia: is it obsolete? // Pacing Clin. Electrophysiol. – 2000. – Vol. 23. – P. 1295–1301.
Tilz R.R., Makimoto H., Lin T. et al. Electrical isolation of a substrate after myocardial infarction: a novel ablation strategy for unmappable ventricular tachycardias: feasibility and clinical outcome // Europace. – 2014. – Vol. 16. – P. 1040– 1052.
Kovacs Boldizsar, Reek Sven, Krasniqi Nazmi, Eriksson Urs, Duru Firat. Extended Use of the Wearable Cardioverter-Deﬁbrillator: Which Patients Are Most Likely to Beneﬁt? Cardiol Res Pract. 2018; 2018: 7373610. Published online 2018 Nov 29. doi: 10.1155/2018/7373610
Barraud Jeremie, Cautela Jennifer, Orabona Morgane, Pinto Johan, Missenard Olivier, Laine Marc, Thuny Franck, Paganelli Franck, Bonello Laurent, Peyrol Michael. Wearable cardioverter deﬁbrillator: Bridge or alternative to implantation? World J Cardiol. 2017 Jun 26; 9(6): 531–538. doi: 10.4330/wjc.v9.i6.531
Epstein A.E., Abraham W.T., Bianco N.R. et al. Wearable cardioverter-deﬁbrillator use in patients perceived to be at high risk early post-myocardial infaretion. J Am Coil Cardio 2013; 62:2000.
Liang J.J., Hodge D.O., Mehta R.A. et al. Outcomes in patients with sustained ventricutar tachyarrhythmias occurring within 48 h of acute myocardial infarction: when is ICD appropriate? Europace 2014; 16:1759-1766.
Myerburg R.J., Wellens H.J.J. Epidemiology of cardiac arrest // In Sudden Cardiac Death. Ed.: S.Priori, D.Zipes. Blackwell Publishing, 2005;304 p.
Zipes D.P. Epidemiology and mechanisms of sudden cardiac death. Can.J.Cardiol. 2005;21(Suppl. A):37A-40A.
Buxton A.E., Lee K.L., Fisher J.D. et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N. Engl. J. Med. 1999; 341(25):1882-1890.
Moss A.J., Hall W.J., Cannom D.S. et al. Improved survival with an implanted deﬁbrillator in patients with coronary disease at high risk for ventricular arrhythmia // N. Engl. J. Med.- 1996.- N. 335.- P. 1933-1940.
Moss A.J., Zareba W., Hall W.J. et al. Prophylactic implantation of a deﬁbrillator in patients with myocardial infarction and reduced ejection fraction // N. Eng. J. Med. – 2002. – N. 346.- P.877- 883.
Bardy G.H, Lee K.L, Mark D.B. et al. Amiodarone or an implantable cardioverter–deﬁbrillator for congestive heart failure. N. Engl. J. Med. 2005; 352:225-37.
Bristow M.R., Saxon L.A., Boehmer J. et al. Cardiac-resynchronization therapy with or without an implantable deﬁbrillator in advanced chronic heart failure. N. Engl. J. Med. 2004; Vol.350. – Р.2140-2150.
Bigger J.T. Prophylactic use of implanted cardiac deﬁbrillators in patients at risk for ventricular arrhythmias after coronary artery bypass graft surgery (Coronary Artery Bypass Graft (CABG) Patch Trial Investigators). New Eng.J.Med.-1997.- Vol.337.- P.1569-1575.
Køber L., Thune J.J., Nielsen J.C. et al. Deﬁbrillator Implantation in Patients with Nonischemic Systolic Heart Failure. Danish Study to Assess the Efﬁcacy of ICDs in Patients with Non- ischemic Systolic Heart Failure on Mortality (DANISH). N Engl J Med 2016; 375:1221-1230.
Bänsch D., Antz M., Boczor S. et al. Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy The Cardiomyopathy Trial (CAT). Circulation. 2002; 105:1453-1458.
Strickberger S.A., Hummel J.D., Bartlett T.G. et al. Amiodarone Versus Implantable Cardioverter- Deﬁbrillator: Randomized Trial in Patients With Nonischemic Dilated Cardiomyopathy and Asymptomatic Nonsustained Ventricular Tachycardia–AMIOVIRT. J Am Coll Cardiol 2003; 41:1707–1712.
Kadish A., Dyer A., Daubert J.P. et al. Prophylactic Deﬁbrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy. Deﬁbrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE). N Engl J Med 2004; 350:2151-2158.
Desai A.S., Fang J.C., Maisel W.H., Baughman K.L. Implantable Deﬁbrillators for the Prevention of Mortality in Patients With Nonischemic Cardiomyopathy A Meta-analysis of Randomized Controlled Trials. JAMA. 2004; 292:2874-2879.
Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350:1417-1424.
Frohlich G.M., Holzmeister J., Hubler M., Hubler S., Wolfrum M., Enseleit F., Seifert B., Hurlimann D., Lehmkuhl H.B., Noll G., Steffel J., Falk V., Luscher T.F., Hetzer R., Ruschitzka F. Prophylacticimp[antablecardioverterdeﬁbrillatortreatmentinpatientswithend- stageheartfailureawaitinghearttransplantation. Heart 2013; 99: 1158-1165.
Sandner S.E., Wieselthaler G., Zuckermann A., Taghavi S., Schmidinger H., Pacher R., Ploner M., Laufer G., Wolner E., Grimm M. Survival beneﬁt of the implantable cardioverter-deﬁbrillator in patients on the waiting list for cardiac transplantation. Circulation 2001; 104:1171-1176.
Van Rijsingen I.A., Arbustini E., Elliott P.M., Mogensen J., Hermans-van Ast J.F., van der Kooi A.J., van Tintelen J.P., van den Berg M.P., Pilotto A., Pasotti M., Jenkins S., Rowland C., Aslam U., Wilde A.A., Perrot A., Pankuweit S., Zwinderman A.H., Charron P., Pinto Y.M. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coil Cardio. 2012; 59:493-500.
Elliott P.M., Anastasakis A., Borger M.A. et al. 2014 ЕОК Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ЕОК). Eur Heart J 2014; 35:2733-2779.
O"Mahony C., Lambiase P.D., Quarta G. et al. The long-term survival and the risks and beneﬁts of imptantabte cardioverter deﬁbrillators in patients with hypertrophic cardiomyopathy. Heart 2012; 98:116-125.
Daubert J.C., Donal E., Linde C. A plea for the wider use of CRT-P in candidates for cardiac resynchronisation therapy. Heart Fail. Rev. 2012;17(6):767-775.
Schinkel A.F. Implantable cardioverter deﬁbrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications. Circ Arrhythm Electrophysiol 2013; 6:562-568.
Dalal D., Molin L.H., Piccini J., Tichnell C., James C., Bomma C., Prakasa K., Towbin J.A., Marcus F.I., Spevak P.J., Bluemke D.A., Abraham T., Russell S.D., Calkins H., Judge D.P. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation 2006; 113:1641-1649.
Wichter T., Paul M., Wollmann C., Acil T., Gerdes P., Ashraf O., Tjan T.D., Soeparwata R., Block M., Borggrefe M., Scheld H.H., Breithardt G., Böcker D. Implantable cardioverter/deﬁbrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long- term follow-up and complications in 60 patients. Circulation 2004; 107:1503-1508.
Ammash N.M., Seward J.B., Bailey K.R., Edwards W.D., Tajik A.J. Clinical proﬁle and outcome of idiopathic restrictive cardiomyopathy. Circulation 2000; 101: 2490-2496.
Maskatia S.A., Decker J.A., Spinner J.A., Kim J.J., Price J.F., Jefferies J.L., Dreyer W.J., Smith E.O., Rossano J.W., Denﬁeld S.W. Restrictive physiology is associated with poor outcomes in children with hypertrophic cardiomyopathy. Pediatr Cardiol 2012; 33:141-149.
Rivenes S.M., Keamey D.L., Smith E.O., Towbin J.A., Denﬁeld S.W. Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. Circulation 2000; 102.:876- 882.
Lipshultz S.E., Orav E.J., Wilkinson J.D., Towbin J.A., Messere J.E., Lowe A.P., Sleeper L.A., Cox G.F., Hsu D.T., Canter C.E., Hunter J.A., Colan S.D. Risk stratiﬁcation at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet 2013; 382.:1889-1897.
Webber S.A., Lipshultz S.E., Sleeper L.A., Lu P., Wilkinson J.D., Addonizio L.J., Canter C.E., Colan S.D., Everitt P.D., Jefferies J.L., Kantor P.F., Lamour J.P., Margossian R., Pahl E., Rusconi P.G., Towbin J.A. Outcomes of restrictive cardiomyopathy in childhood and the inﬂuence of phenotype: a report from the Pediatric Cardiomyopathy Registry. Circulation 2012; 12.6:1237- 1244.
Schwartz P.J., Spazzolini C., Priori S.G. et al. Who are the Iong-QT syndrome patients who receive an implantable cardioverter-deﬁbrillator and what happens to them?: data from the European Long-QT Syndrome Imp[antable Cardioverter-Deﬁbrillator (LQTS ICD) Registry. Circulation 2010; 122:1272-1282.
Jons C., Moss A.J., Goldenberg I., Liu J., McNitt S., Zareba W., Robinson J.L. Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol 2010; 55:783 -788.
Priori S.G., Schwartz P.J., Napolitano C. et al. Risk stratiﬁcation in the long-QT syndrome. N Engl J Med 2003; 348:1866-1874.
Mazzanti A., Kanthan A., Monteforte N. et al. Novel insight into the natural history of short QT syndrome. J Am Coil Cardiol 2014; 63:1300-1308.
Gaita F., Giustetto C., Bianchi F., Wolpert C., Schimpf R., Riccardi R., Grossi S., Richiardi E., Borggrefe M. Short QT syndrome: a familial cause of sudden death. Circulation 2003; 108:965- 970.
Priori S.G., Napolitano C., Gasparini M. et al. Natural history of Brugada syndrome: insights for risk stratiﬁcation and management. Circulation 2002; 105:1342-1347.
Priori S.G., Napolitano C., Memmi M. et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106: 69-74.
Hayashi M., Denjoy I., Extramiana F., Maltret A., Buisson NR., Lupoglazoff J.M., Klug D., Takatsuki S., Villain E., Kamblock J., Messali A., Guicheney P., Lunardi J., Leenhardt A. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricutar tachycardia. Circulation 2009; 119:2426-2434.
Kristen A.V., Dengler T.J., Hegenbart U., Schonland S.O., Goldschmidt H., Sack F.U., Voss F., Becker R., Katus H.A., Bauer A. Prophylactic implantation of cardioverter deﬁbrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008; S:235-240.
Palladini G., Malamani G., Co F., Pistorio A., Recusani F., Anesi E., Garini P., Merlini G. Holter monitoring in AL amyloidosis: prognostic implications. Paring Ciin Electrophysiol 2001; 24:1228-1233.
Dubrey S.W., Bilazarian S., LaValley M., Reisinger J., Skinner M., Falk R.H. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J 1997; 134:994-1001.
Reisinger J., Dubrey S.W., LaValley M,, Skinner M,, Falk R,H. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coil Cardiol 1997; 30:1046-1051.
Te A.L., Lin Y.J., Chen Y.Y., Chung F.P., Chang S.L., Lo L.W., Hu Y.F., Tuan T.C., Chao T..F, Liao J.N., Lin C.Y., Chang Y.T., Chien K.L., Chen S.A. Increased risk of ventricular tachycardia in patients with sarcoidosis during the very long term follow-up. Int J Cardiol. 2017; 228:68–73. doi: 10.1016/j.ijcard.2016.11.041.
Muratore C.A., Batista Sa L.A., Chiate P.A., Eloy R., Tentori M.C., Escudero J., Lima A.M., Medina L.E., Garillo R., Maloney J. Implantable cardioverter deﬁbrillators and Chagas" disease: results of the ICD Registry Latin America. Europace 2009; 11: 164-168.
Martinelli L., de Siqueira S.F., Sternick E.B., Rassi A.Jr, Costa R., Ramires J.A., Kalil Filho R. Long-term follow-up of implantable cardioverter-deﬁbrillator for secondary prevention in Chagas" heartdisease. Am J Cardiol 2012; 110:1040-1045.
Barbosa M.P., da Costa Rocha M.O., de Oliveira A.B., Lombardi F., Ribeiro A.L. Efﬁcacy and safety of implantable cardioverter-deﬁbrillators in patients with Chagas disease. Europace 2013; 15:957-962.
Gali W.L., Sarabanda A.V., Baggio J.M., Ferreira L.G., Gomes G.G., Marin-Neto J.A., Junqueira L.F. Implantable cardioverter-deﬁbrillators for treatment of sustained ventricular arrhythmias in patients with Chagas" heart disease: comparison with a control group treated with amiodarone alone. Europace 2014; 16:674-680.
Courtney E. Bennett, Ronald Freudenberger. The Current Approach to Diagnosis and Management of Left Ventricular Noncompaction Cardiomyopathy: Review of the Literature. Cardiology Research and Practice Volume 2016. 7 pages http://dx.doi.org/10.1155/2016/5172308.
Khairy P., Harris L., Landzberg M.J., Viswanathan S., Barrow A., Gatzoulis M.A., Fernandes S.M., Beauchesne L., Therrien J., Chetailte P., Gordon E., Vonder Muhll I., Cecchin F. Implantable cardioverter-deﬁbrillators in tetralogy of Fatlot. Circulation 2008; 117:363-370.
Khairy P., Harris L., Landzberg M.J., Fernandes S.M., Barrow A., Mercier L.A., Viswanathan S., Chetaille P., Gordon E., Dore A., Cecchin F. Sudden death and deﬁbrillators in transposition of the great arteries with intra-atrial bafﬂes: a multicenter study. Circ Arrhythm Electrophysiol 2008; 1:250-257.
Berul C.I., Van Hare G.F., Kertesz N.J., Dubin A.M., Cecchin F., Collins K.K., Cannon B.C., Alexander M.E., Triedman J.K., Walsh E.P., Friedman R.A. Results of a multicenter retrospective imptantable cardioverter-deﬁbrillator registry of pediatric and congenital heart disease patients. J Am Coil Cardiol 2008; 51:1685-1691.
Koyak Z., de Groot J.R., Van Gelder I.C., Bouma B.J., van Desset P.F., Budts W., van Erven L., van Dijk A.P., Wilde A.A., Pieper P.G., Sieswerda G.T. Imptantable cardioverter deﬁbrillator therapy in adults with congenital heart disease: who is at risk of shocks? Circ Arrhythm Electrophysiol 2012; 5:101 - 110.
Zeppenfeld K., Schalij M.J., Bartelings M.M., Tedrow U.B., Koplan B.A., Soejima K., Stevenson W.G. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identiﬁcation of the critical right ventricutar isthmus. Circulation 2007; 116:2241-2252.
Gallego P., Gonzalez A.E., Sanchez-Recalde A., Peinado R., Polo L., Gomez-Rubin C., Lopez- Sendon J.L., Oliver J.M. Incidence and predictors of sudden cardiac arrest in adults with congenital heart defects repaired before adult life. Am J Cardiol 2012; 110:109-117.
Ghai A., Silversides C., Harris L., Webb G.D., Siu S.C., Therrien J. Left ventricular dysfunction is a risk factor for sudden cardiac death in adults late after repair of tetralogy of Fallot. J Am Coil Cardiol 2002; 48:1675 – 1680.
Gatzoulis H.A., Bataji S., Webber S.A., Siu S.C., Hokanson J.S., Poite C., Rosenthal M., Nakazawa M., Motter J.H., Gillette P.C., Webb G.D., Redington A.N. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 2000;. 356:975- 981.
Cleland J.G.F., Daubert J.C., Erdmann E. et all. The CARE-HF study (Cardiac Resynchronisation in Heart Failure study): rationale, design and end-points. Eur. J. Heart Fail. 2001; 3(4):481-489.
Tang A.S.L., Wells G.A., Talajic M. et al. Cardiac-resynchronization therapy for mild-to- moderate heart failure. N. Engl. J. Med. 2010; 363(25):2385-2395.
Strik M., Middendorp L., Vernooy K. Animal models of dyssynchrony. J. of Cardiovasc. Trans. Res. 2012; 5:135-145. Eickolt C., Siekiera M., Kirmanoglou K. et al. Improvement of left ventricular function under cardiac resynchronization therapy goes along with a reduced incidence of ventricular arrhythmia. PloS ONE 2012; 7(11):1-7.
Young J.B., Abraham W.T., Smith A.L. et al. Combined Cardiac Resynchronization and Implantable Cardioversion Deﬁbrillation in Advanced Chronic Heart Failure The MIRACLE ICD Trial. JAMA 2003; 289(20):2685-2694.
Bradley D.J., Bradley E.A., Baughman K.L. et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 2003; 289(6):730-740.
Abraham W.T. Cardiac resynchronization therapy. Prog. Cardiovasc. Dis. 2006; 48(4):232-238.
McAlister F.A., Ezekowitz J.A., Wiebe N. et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann. Intern. Med. 2004; 141(5):381-390.
Bogale N., Priori S., Cleland J.G. et al. The European CRT Survey: 1 year (9-15 months) follow-up results. Eur. J. Heart Fail. 2012; 14(1):61-73.
Rivero-Ayerza M., Theuns D.A.M.J., Garcia-Garcia H. et al. Effects of cardiac resynchronization therapy on all cause mortality, mode of death and heart failure hospitalizations. A meta-analysis of randomized controlled trials. Eur. Heart J. 2006; 27: Abstract Suppl.608.
Cleland J.G.F., Coletta A.P., Lammiman M. et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE./ Eur. J. Heart Fail. 2005; 7(6):1070- 1075.
Cleland J.G.F., Daubert J.C., Erdmann E. et all. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur. Heart J. 2006; 27(16):1928-1932.
Daubert C., Gold M.R., Abraham W.T. et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: Insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J. Am. Coll. Cardiol. 2009; 54(20):1837-1846.
Linde C., Gold M.R., Abraham W.T., St John Sutton M., Ghio S., Cerkvenik J., Daubert C. Long- term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J 2013; 34:2592–2599.
Cleland J.G., Abraham W.T., Linde C. et al. An individual patient meta-analysis of ﬁve randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013;.34:3547–3556.
Woods B., Hawkins N., Mealing S. et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart 2015; 101:1800–1806.
Steffel J., Robertson M., Singh J.P. et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J 2015; 36:1983–1989.
Jacobsson J, Reitan C, Carlson J, Borgquist R, Platonov PG. Atrial ﬁbrillation incidence and impact of biventricular pacing on long-term outcome in patients with heart failure treated with cardiac resynchronization therapy. BMC Cardiovasc Disord. 2019 Aug 13;19(1):195. doi: 10.1186/s12872-019-1169-1.
Healey Jeff S.; Hohnloser Stefan H.; Exner Derek V. et al. Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail. 2012;5:566-570. DOI: 10.1161/CIRCHEARTFAILURE.112.968867.
Lopes Cláudia, Pereira Telmo, Barra Sérgio. Cardiac resynchronization therapy in patients with atrial ﬁbrillation: a meta-analysis. Rev Port Cardiol. 2014 Nov;33(11):717-25. doi: 10.1016/j.repc.2014.05.008..
Gasparini M, Leclercq C, Lunati M, Landolina M, Auricchio A, Santini M, Boriani G, Lamp B, Proclemer A, Curnis A, Klersy C, Leyva F. Cardiac resynchronization therapy in patients with atrial ﬁbrillation: the CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail. 2013 Dec;1(6):500-7. doi: 10.1016/j.jchf.2013.06.003. Epub 2013 Oct 23.
Upadhyay G.A., Choudhry N.K., Auricchio A., Ruskin J., Singh J.P. Cardiac resynchronization in patients with atrial ﬁbrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol 2008; 52:1239–1246.
Gasparini M., Leclercq C., Lunati M. et al. Cardiac resynchronization therapy in patients with atrial ﬁbrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail 2013; 1:500–507.
Gasparini M., Auricchio A., Regoli F. et al. Four-Year Efﬁcacy of Cardiac Resynchronization Therapy on Exercise Tolerance and Disease Progression: The Importance of Performing Atrioventricular Junction Ablation in Patients With Atrial Fibrillation. J. Am. Coll. Cardiol. 2006; 48(4):734-743.
Leclercq C., Walker S., Linde C. et al. Comparative effects of permanent biventricular and right- univentricular pacing in heart failure patients with chronic atrial ﬁbrillation. Eur Heart J 2002; 23:1780–1787.
Koplan B.A., Kaplan A.J., Weiner S., Jones P.W., Seth M., Christman S.A. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol 2009; 53:355–360.
Tolosana J.M., Hernandez Madrid A. et al. Comparison of beneﬁts and mortality in cardiac resynchronization therapy in patients with atrial ﬁbrillation versus patients in sinus rhythm (Results of the Spanish Atrial Fibrillation and Resynchronization [SPARE] Study). Am J Cardiol 2008; 102:444–449.
Ferreira A.M., Adragao P., Cavaco D.M., Candeias R., Morgado F.B., Santos K.R., Santos E., Silva J.A. Beneﬁt of cardiac resynchronization therapy in atrial ﬁbrillation patients vs. patients in sinus rhythm: the role of atrioventricular junction ablation. Europace 2008; 10:809–815.
Ganesan A.N., Brooks A.G., Roberts-Thomson K.C., Lau D.H., Kalman J.M., Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial ﬁbrillation and heart failure a systematic review. J Am Coll Cardiol 2012; 59:719–726.
Orlov M.V., Gardin J.M., Slawsky M., Bess R.L., Cohen G., Bailey W., Plumb V., Flathmann H., de Metz K. Biventricular pacing improves cardiac function and prevents further left atrial remodeling in patients with symptomatic atrial ﬁbrillation after atrioventricular node ablation. Am Heart J 2010; 159:264–270.
Doshi R.N., Daoud E.G., Fellows C., Turk K., Duran A., Hamdan M.H., Pires L.A. Left ventricular- based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005; 16:1160–1165.
Brignole M., Gammage M., Puggioni E., Alboni P., Raviele A., Sutton R., Vardas P., Bongiorni M.G., Bergfeldt L., Menozzi C., Musso G. Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial ﬁbrillation. Eur Heart J 2005; 26:712–722.
Brignole M., Botto G.L., Mont L. et al. Predictors of clinical efﬁcacy of ’Ablate and Pace’ therapy in patients with permanent atrial ﬁbrillation. Heart 2012; 98:297–302.
Бокерия Л.А., Неминущий Н.М., Постол А.С. Сердечная ресинхронизирующая терапия. Формирование показаний и современные подходы к повышению эффективности метода. Комплексные проблемы сердечно-сосудистых заболеваний 2018; 7 (3): 102-116. DOI: 10.17802/2306-1278-2018-7-3-102-116.
Stavrakis S., Garabelli P., Reynolds D.W. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial ﬁbrillation: ameta-analysis. Europace 2012; 14(10):1490-1497.
Curtis A.B., Worley S.J., Adamson P.B. et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013; 368:1585–1593.
Bogale N., Witte K., Priori S., Cleland J., Auricchio A., Gadler F., Gitt A., Limbourg T., Linde C., Dickstein K. The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. Eur J Heart Fail 2011; 13:974–983.
Leclercq C., Cazeau S., Lellouche D., Fossati F., Anselme F., Davy J.M., Sadoul N., Klug D., Mollo L., Daubert J.C. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: The RD-CHF Study. Pacing Clin Electrophysiol 2007; 30 Suppl 1:S23–30.
Hoijer C.J., Meurling C., Brandt J. Upgrade to biventricular pacing in patients with conventional pacemakers and heart failure: a double-blind, randomized crossover study. Europace 2006; 8:51–55.
Van Geldorp I.E., Vernooy K., Delhaas T., Prins M.H., Crijns H.J., Prinzen F.W., Dijkman B. Beneﬁcial effects of biventricular pacing in chronically right ventricular paced patients with mild cardiomyopathy. Europace 2010; 12:223–229.
Laurenzi F., Achilli A., Avella A., Peraldo C., Orazi S., Perego G.B., Cesario A., Valsecchi S., De Santo T., Puglisi A., Tondo C. Biventricular upgrading in patients with conventional pacing system and congestive heart failure: results and response predictors. Pacing Clin Electrophysiol 2007; 30:1096–1104.
Vatankulu M.A., Goktekin O., Kaya M.G., Ayhan S., Kucukdurmaz Z., Sutton R., Henein M. Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices. Am J Cardiol 2009; 103:1280–1284.
Foley P.W., Muhyaldeen S.A., Chalil S., Smith R.E., Sanderson J.E., Leyva F. Long-term effects of upgrading from right ventricular pacing to cardiac resynchronization therapy in patients with heart failure. Europace 2009; 11:495–501.
Frohlich G., Steffel J., Hurlimann D., Enseleit F., Luscher T.F., Ruschitzka F., Abraham W.T., Holzmeister J. Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodelling. Eur Heart J 2010; 31:1477–1485.
Paparella G., Sciarra L., Capulzini L., Francesconi A., De Asmundis C., Sarkozy A., Cazzin R., Brugada P. Long-term effects of upgrading to biventricular pacing: differences with cardiac resynchronization therapy as primary indication. Pacing Clin Electrophysiol 2010; 33:841–849.
Gage R.M., Burns K.V., Bank A.J. Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing. Eur J Heart Fail 2014; 16:1199–1205.
Bardy G.H., Smith W.M., Hood M.A. et al. An entirely subcutaneous implantable cardioverter- deﬁbrillator. N Engl J Med. 2010; 363:36-44.
Weiss R., Knight B.P., Gold M.R., Leon A.R., Herre J.M., Hood M., Rashtian M., Kremers M., Crozier I., Lee K.L., Smith W., Burke M.C. Safety and efﬁcacy of a totally subcutaneous implantable-cardioverter deﬁbrillator. Circulation 2013; 128: 944-953.
Jarman J.W., Lascelles K., Wong T., Markides V., Clague J.R., Till J. Clinical experience of entirely subcutaneous implantable cardioverter-deﬁbrillators in children and adults: cause for caution. Eur Heart J. 2012; 33:1351-1359.
Dabiri Abkenari L., Theuns D.A., Valk S.D. et al. Clinical experience with a novel subcutaneous implantable deﬁbrillator system in a single center. Clin Res Cardiol 2011; 108:737-744.
Burke M.C., Gold M.R., Knight B.P. et al. Safety and efﬁcacy of the totally subcutaneous implantable deﬁbrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. J Am Coil Cardiol 2015; 65: 1605-1615.
Lambiase P.D., Barr C., Theuns D.A. et al. Worldwide experience with a totally subcutaneous implantable deﬁbrillator: early results from the EFFORTLESS S-ICD Registry. Eur HeartJ 2014; 35:1657-1665.
Auricchio A., Klein H., Geller C.J., Reek S., Heilman M.S., Szymkiewicz S.J. Clinical efﬁcacy of the wearable cardioverter-deﬁbrillator in acutely terminating episodes of ventricular ﬁbrillation. Am J Cardiol. 1998;81:125 3-1256.
Klein H.U., Goldenberg I., Moss A.J. Risk stratiﬁcation for implantable cardioverter deﬁbrillator therapy: the role of the wearable cardioverter-deﬁbrillator. Eur Heart J 2013; 34:2230-2242.
Kao A.C., Krause S.W., Handa R., Karia D., Reyes G., Bianco N.R., Szymkiewicz S.J., Wearable deﬁbrillator use In heart Failure (WIF) Investigators. Wearable deﬁbrillator use in heart failure (WIF): results of a prospective registry. BMC Cardiovasc Disord 2012; 12:123.
Adler A., Halkin A., Viskin S. Wearable cardioverter-deﬁbrillators. Circulation 2013; 127:854- 860.
Hallstrom A.P., Omato J.P., Weisfeldt M. et al. Public-access deﬁbrillation and survival after out- of-hospital cardiac arrest. N Engl J Med. 2004; 351:637-646.
Capucci A., Aschieri D., Piepoli M.F., Bardy G.H., Iconomu E., Arvedi M. Tripling survival from sudden cardiac arrest via early deﬁbrillation without traditional education in cardiopulmonary resuscitation. Circulation 2002; 106:1065-1070.
De Vreede-Swagemakers J.J., Gorgels A.P., Dubois-Arbouw W.I. et al. Out-of-hospital cardiac arrest in the 1990"s: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30:1500-1505.
Tomzik Juliane, Koltermann Katharina C., Zabel Markus, Willich Stefan N., Reinhold Thomas. Quality of Life in Patients with an Implantable Cardioverter Deﬁbrillator: A Systematic Review. Front Cardiovasc Med. 2015; 2: 34. doi: 10.3389/fcvm.2015.00034.
Schron E.B., Exner D.V., Yao Q., Jenkins L.S., Steinberg J.S., Cook J.R., Kutalek S.P., Friedman P.L., Bubien R.S., Page R.L., Powell J. Quality of life in the antiarrhythmics versus implantable deﬁbrillators trial impact of therapy and inﬂuence of adverse symptoms and deﬁbrillator shocks. Circulation 2002; 105:589-594.
Koopman H.M., Vrijmoet-Wiersma C.M., Langius J.N., van den Heuvel F., Clur S.A., Blank C.A., Biota N.A., ten Harkel A.D. Psychological functioning and disease-related quality of life in pediatric patients with an implantable cardioverter deﬁbrillator. Pediatr Cardiol 2012; 33:569- 575.
Padeletti L., Arnar D.O., Boncinelli L. et al. EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace 2010; 12: 1480-1489.
Jaarsma T., Beattie J.M., Ryder M., Rutten F.H., McDonagh T., Mohacsi P., Murray S.A., Grodzicki T., Bergh I., Metra M., Ekman I., Angermann C., Leventhal M., Pitsis A., Anker S.D., Gavazzi A., Ponikowski P., Dickstein K., Delacretaz E., Blue L., Strasser F., McMurray J. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11:433-443.
Wathen M.S., DeGroot P.J., Sweeney M.O. et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-deﬁbrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004; 110; 2591-2596.
Sweeney M.O., Wathen M.S., Volosin K. et al. Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Deﬁbrillator Patients Results From the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) Trial. Circulation 2005; 111;2898-2905.
Borne R.T., Varosy P.D., Masoudi F.A. Implantable cardioverter-deﬁbrillator shocks: epidemiology, outcomes, and therapeutic approaches. JAMA Intern Med 2013; 173: 859-865.
Berg S.K., Higgins M., Reilly C.M., Langberg J.J., Dunbar S.B. Sleep quality and sleepiness in persons with implantable cardioverter deﬁbrillators: outcome from a clinical randomized longitudinal trial. Pacing Clin Electrophysiol 2012; 35:431-443.
Vazquez L.D., Kuhl E.A., Shea J.B., Kirkness A., Lemon J., Whalley D., Conti J.B., SearsSF. Age- speciﬁc differences in women with implantable cardioverter deﬁbrillators: an international multicenter study. Pacing Clin Electrophysiol 2008; 31:1528-1534.
Morady F., Kadish A.H., DiCarlo L., Kou W.H., Winston S., de Buitlier M., Calkins H., Rosenheck S., Sousa J. Long term results of catheter ablation of idiopathic right ventricular tachycardia. Circulation 1990; 82:2093-2099.
Callans D.J., Menz V., Schwartzman D., Gottlieb C.D., Marchlinski F.E. Repetitive monomorphic tachycardia from the left ventricular outﬂow tract: electrocardiographic patterns consistent with a left ventricular site of origin. J Am Coll Cardiol 1997; 29:1023-1027.
Tada H., Hiratsuji T., Naito S., Kurosaki K., Ueda M., Ira S., Shinbo G., Hoshizaki H., Oshima S., Nogami A., Taniguchi K. Prevalence and characteristics of idiopathic outﬂow tract tachycardia with QRS alteration following catheter ablation requiring additional radiofrequency ablation at a different point in the outﬂow tract. Pacing Clin Electrophysiol 2004; 27:1240-1249.
Yamada T., McElderry H.T., Doppalapudi H., Murakami Y., Yoshida Y., Yoshida N., Okada T., Tsuboi N., Inden Y., Murohara T., Epstein A.E., Plumb V.J., Singh S.P., Kay G.N. Idiopathic ventricular arrhythmias originating from the aortic root prevalence, electrocardiographic and electrophysiologic characteristics, and results of radiofrequency catheter ablation. J Am Coil Cardiol 2008; 52:139-147.
Daniels D.V., Lu Y.Y., Morton J.B., Santucci P.A., Akar J.G., Green A., Wilber D.J. Idiopathic epicardial left ventricular tachycardia originating remote from the sinus of Valsalva: electrophysiological characteristics, catheter ablation, and identiﬁcation from the 12-1ead electrocardiogram. Circulation 2006; I 13:1659-1666.
Tada H., Nogami A., Naito S., Fukazawa H., Horie Y., Kubota S., Okamoto Y., Hoshizaki H., Oshima S., Taniguchi K. Left ventricular epicardial outﬂow tract tachycardia: a new distinct subgroup of outﬂow tract tachycardia. Jpn Circ J 2001; 65:723 -730.
Yamada T., McElderry H.T., Doppalapudi H., Okada T., Murakami Y., Yoshida Y., Yoshida N., Inden Y., Murohara T., Plumb V.J., Kay G.N. Idiopathic ventricular arrhythmias originating from the left ventricular summit: anatomic concepts relevant to ablation. Circ Arrhythm Electrophysiol 2010 ;3:616-623.
Kumagai K., Yamauchi Y., Takahashi A., Yokoyama Y., Sekiguchi Y., Watanabe J., Iesaka Y., Shirato K., Aonuma K. Idiopathic left ventricular tachycardia originating from the mitral annulus. J Cardiovasc Electrophysiol 2005; 16:1029-1036.
Yamada T., Litovsky S.H., Kay G.N. The left ventricular ostium: an anatomic concept relevant to idiopathic ventricular arrhythmias. Circ Arrhythm Electrophysiol 2008; 1: 396-404.
Kanagaratnam L., Tomassoni G., Schweikert R., Pavia S., Bash D., Beheiry S., Neibauer M., Saliba W., Chung M., Tchou P., Natale A. Ventricular tachycardias arising from the aortic sinus of valsalva: an under-recognized variant of left outﬂow tract ventricular tachycardia. J Am Coil Cardiol 2001; 37:1408-1414.
Ouyang F., Fotuhi P., Ha S.Y., Hebe J., Volkmer M., Goya M., Burns M., Antz M., Ernst S., Cappato R., Kuck K.H. Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: electrocardiographic characterization for guiding catheter ablation. J Am Coil Cardiol 2002; 39:500-508.
Tada H., Tadokoro K., Miyaji K., Ira S., Kurosaki K., Kaseno K., Naito S., Nogami A., Oshima S., Taniguchi K. Idiopathic ventricular arrhythmias arising from the pulmonary artery: prevalence, characteristics, and topography of the arrhythmia origin. Heart Rhythm 2008; 5:419-426.
Sekiguchi Y., Aonuma K., Takahashi A., Yamauchi Y., Hachiya H., Yokoyama Y., IesakaY., Isobe M. Electrocardiographic and electrophysiologic characteristics of ventricular tachycardia originating within the pulmonary artery. J Am Coil Cardiol 2005; 45:887-895.
Timmermans C., Rodriguez L.M., Crijns H.J., Moorman A.F., Wellens H.J. Idiopathic left bundle- branch block-shaped ventricular tachycardia may originate above the pulmonary valve. Circulation 2003; 108:1960-1967.
Sung R.J., Keung E.C., Nguyen N.X., Huycke E.C. Effects of beta-adrenergic blockade on verapamil-responsive and verapamil-irresponsive sustained ventricular tachycardias. J Clin Invest 1988; 81:688-699.
Lerman B.B., Belardinelli L., West G.A., Berne R.M., DiMarco J.P. Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity. Circulation 1986; 74:270-280.
Lerman B.B. Response of nonreentrant catecholamine-mediated ventricular tachycardia to endogenous adenosine and acetylcholine. Evidence for myocardial receptor-mediated effects. Circulation 1993; 87:382-390.
Wilber D.J., Baerman J., Olshansky B., Kall J., Kopp D. Adenosine-sensitive ventricular tachycardia. Clinical characteristics and response to catheter ablation. Circulation 1993; 87:126- 134.
Marchlinski F.E., Deely M.P., Zado E.S. Sex-speciﬁc triggers for right ventricular outﬂow tract tachycardia. Am Heart J 2000; 139:1009-1013.
Krittayaphong R., Saiviroonporn P., Boonyasirinant T., Nakyen S., Thanapiboonpol P., Watanaprakarnchai W., Ruksakul K., Kangkagate C. Magnetic resonance imaging abnormalities in right ventricular outﬂow tract tachycardia and the prediction of radiofrequency ablation outcome. Pacing Clin Electrophysiol 2006; 29:837-845.
Khasnis A., Jongnarangsin K., Abela G., Veerareddy S., Reddy V., Thakur R. Tachycardia-induced cardiomyopathy: a review of literature. Pacing Clin Electrophysiol 2005; 28:710-721.
O"Donnell D., Cox D., Bourke J., Mitchell L., Furniss S. Clinical and electrophysiological differences between patients with arrhythmogenic right ventricular dysplasia and right ventricular outﬂow tract tachycardia. Eur HeartJ 2003; 24:801-810.
Ito S., Tada H., Naito S., Kurosaki K., Ueda M., Hoshizaki H., Miyamori I., Oshima S., Taniguchi K., Nogami A. Development and validation of an ECG algorithm for identifying the optimal ablation site for idiopathic ventricular outﬂow tract tachycardia. J Cardiovasc Electrophysiol 2003; 14:1280-1286.
Koruth J.S., Aryana A., Dukkipati S.R., Pak H.N., Kim Y.H., Sosa E.A., Scanavacca M., Mahapatra S., Ailawadi G., Reddy V.Y., d"Avila A. Unusual complications of percutaneous epicardial access and epicardial mapping and ablation of cardiac arrhythmias. Circ Arrhythm Electrophysiol 2011; 4:882-888.
Roberts-Thomson K.C., Steven D., Seller J., Inada K., Koplan B.A., Tedrow U.B., Epstein L.M., Stevenson W.G. Coronary artery injury due to catheter ablation in adults: presentations and outcomes. Circulation 2009; 120:1465- 1473.
Makimoto H., Zhang Q., Tilz R.R., Wissner E., Cuneo A., Kuck K.H., Ouyang F. Aborted sudden cardiac death due to radiofrequency ablation within the coronary sinus and subsequent total occlusion of the circumﬂex artery. J Cardiovasc Electrophysiol 2013; 24:929-932.
Ho Y.S. Overview of cardiac anatomy relevant to catheter ablation. In: Wilber D., Packer D., Stevenson W., eds. Catheter Ablation of Cardiac Arrhythmias, 3rd edn. Cambridge, MA: Blackwell Scientiﬁc; 2008: 3-17.
Prystowsky E.N., Padanilam B.J., Joshi S., Fogel R.I. Ventricular arrhythmias in the absence of structural heart disease. J Am Coil Cardiol 2012; S?:1733-1744.
Klein L.S., Shih H.T., Hackett F.K., Zipes D.P., Miles W.M. Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease. Circulation 1992; 8S:1666- 1674.
Lin D., Hsia H.H., Gerstenfeld E.P., Dixit S., Callans D.J., Nayak H., Russo A., Marchlinski F.E. Idiopathic fascicular left ventricular tachycardia: linear ablation lesion strategy for noninducible or nonsustained tachycardia. Heart Rhythm 2005; 2: 934-939.
Crijns H.J., Smeets J.L., Rodriguez L.M., Meijer A., Wellens H.J. Cure of interfascicular reentrant ventricular tachycardia by ablation of the anteriorfascicle of the left bundle branch. J Cardiovasc Electrophysiol. 1995; 6:486-492.
Ohe T., Shimomura K., Aihara N., Kamakura S., Matsuhisa M., Sato I., Nakagawa H., Shimizu A. Idiopathic sustained left ventricular tachycardia: clinical and electrophysiologic characteristics. Circulation 1988; 77:560-568.
Ouyang F., Cappato R., Ernst S., Goya M., Volkmer M., Hebe J., Antz M., Vogtmann T., Schaumann A., Fotuhi P., Hoffmann-Riem M., Kuck K.H. Electroanatomic substrate of idiopathic left ventricular tachycardia: unidirectional block and macroreentry within the Purkinje network. Circulation 2002; 10S:462-469.
Ma F.S., Ma J., Tang K., Han H., Jia Y.H., Fang P.H., Chu J.M., Pu J.L., Zhang S. Left posterior fascicular block: a new end point of ablation for verapamil-sensitive idiopathic ventricular tachycardia. Chin Med J (Engl) 2006; 119:367-372.
Kottkamp H., Chen X., Hindricks G., Willems S., Haverkamp W., Wichter T., Breithardt G., Borggrefe M. Idiopathic left ventricular tachycardia: new insights into electrophysiological characteristics and radiofrequency catheter ablation. Pacing Clin Electrophysiol. 1995; 18:1285- 1297.
Nogami A., Naito S., Tada H., Oshima S., Taniguchi K., Aonuma K., Iesaka Y. Verapamil-sensitive left anterior fascicular ventricular tachycardia: results of radiofrequency ablation in six patients. J Cardiovasc Electrophysiol 1998; 9: 1269 – 1278.
Reithmann C., Hahnefeld A., Ulbrich M., Matis T., Steinbeck G. Different forms of ventricular tachycardia involving the left anterior fascicle in nonischemic cardiomyopathy: critical sites of the reentrant circuit in low-voltage areas. J Cardiovasc Electrophysiol 2009; 20:841-849.
Bogun F., EI-Atassi R., Daoud E., Man K.C., Strickberger S.A., Morady F. Radiofrequency ablation of idiopathic left anterior fascicular tachycardia. J Cardiovasc Electrophysiol. 1995; 6:1113-1116.
Caceres J., Jazayeri P., McKinnie J., Avitall B., Denker S.T., Tchou P., Akhtar P. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation 1989; 79:256-270.
Tchou P., Jazayeri M., Denker S., Dongas J., Caceres J., Akhtar P. Transcatheter electrical ablation of right bundle branch. A method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry. Circulation 1988; 78: 246-257.
Mizusawa Y., Sakurada H., Nishizaki M., Ueda-Tatsumoto A., Fukamizu S., Hiraoka M. Characteristics of bundle branch reentrant ventricular tachycardia with a right bundle branch block conﬁguration: feasibility of atrial pacing. Europace 2009; 11: 1208-1213.
Nogami A. Purkinje-related arrhythmias part I: monomorphic ventricular tachycardias. Pacing Clin Electrophysiol 2011; 34:624-650.
Doppalapudi H., Yamada T., McElderry H.T., Plumb V.J., Epstein A.E., Kay G.N. Ventricular tachycardia originating from the posterior papillary muscle in the left ventricle: a distinct clinical syndrome. Circ Arrhythm Electrophysiol 2008; 1:23-29.
Crawford T., Mueller G., Good E., Jongnarangsin K., Chugh A., Pelosi F.Jr, Ebinger M., Oral H., Morady F., Bogun F. Ventricular arrhythmias originating from papillary muscles in the right ventricle. Heart Rhythm 2010; 7:725-730.
Bogun F., Desjardins B., Crawford T., Good E., Jongnarangsin K., Oral H., Chugh A., Pelosi F., Morady F. Postinfarction ventricular arrhythmias originating in papillary musdes. J Am Coil Cardiol 2008; S1:1794-1802.
Yeh S.J., Wen M.S., Wang C.C., Lin F.C., Wu D. Adenosine-sensitive ventricular tachycardia from the anterobasal left ventricle. J Am Coil Cardiol. 1997; 38:1339-1345.
Kondo K., Watanabe I., Kojima T., Nakai T., Yanagawa S., Sugimura H., Shindo A., Oshikawa N., Masaki R., Saito S., Ozawa Y., Kanmatsuse K. Radiofrequency catheter ablation of ventricular tachycardia from the anterobasal left ventricle. Jpn Heart J 2000; 41:215 – 225.
Tada H., Ito S., Naito S., Kurosaki K., Kubota S., Sugiyasu A., Tsuchiya T., Miyaji K., Yamada M., Kutsumi Y., Oshima S., Nogami A., Taniguchi K. Idiopathic ventricular arrhythmia arising from the mitral annulus: a distinct subgroup of idiopathic ventricular arrhythmias. J Am Coil Cardiol 2005; 4S:877-886.
Haissaguerre M., Derval N., Sachet F., Jeset L., Deisenhofer I., deRoy L., Pasquie J.L., Nogami A., Babuty D., Yli-Mayry S., DeChittou C., Scanu P., Mabo P., Matsuo S., Probst V., Le Scouarnec S., Defaye P., Schtaepfer J., Rostock T., Lacroix D., Lamaison D., Lavergne T., Aizawa Y., Engtund A., Ansetme F., O"Neill M., Hocini M., Lira K.T., Knecht S., Veenhuyzen G..D, Bordachar P., Chauvin M., Jais P., Coureau G., Chene G., Klein G.J., Clementy J. Sudden cardiac arrest associated with early repotarization. N Engl J Med 2008; 358:2016-2023.
Haissaguerre M., Shah D.C., Jais P., Shoda M., Kautzner J., Arentz T., Kalushe D., Kadish A., Grifﬁth M., Gaita F., Yamane T., Garrigue S., Hocini M., Clementy J. Role of Purkinje conducting system in triggering of idiopathic ventricular ﬁbrillation. Lancet 2002; 3S9:677-678.
Bogun F., Good E., Reich S., Elmouchi D., Igic P., Tschopp D., Dey S., Wimmer A., Jongnarangsin K., Oral H., Chugh A., Pelosi F., Morady F. Role of Purkinje ﬁbers in post-infarction ventricular tachycardia. J Am Coil Cardiol 2006; 48:2500-2507.
Haissaguerre M., Shoda M., Jais P., Nogami A., Shah D.C., Kautzner J., Arentz T., Kalushe D., Lamaison D., Grifﬁth M., Cruz F., de Paola A., Gaita F., Hocini M., Garrigue S., Macle L., Weerasooriya R., Clementy J. Mapping and ablation of idiopathic ventricular ﬁbrillation. Circulation 2002; 106:962-967.
Knecht S., Sacher F., Wright M., Hocini M., Nogami A., Arentz T., Petit B., Franck R., De Chillou C., Lamaison D., Farre J., Lavergne T., Verbeet T., Nault I., Matsuo S., Leroux L., Weerasooriya R., Cauchemez B., Lellouche N., Derval N., Narayan S.M., Jais P., Clementy J., Haissaguerre M. Long- term follow-up of idiopathic ventricular ﬁbrillation ablation: a multicenter study. J Am Coil Cardiol 2009; S4:522-528.
Nogami A., Sugiyasu A., Kubota S., Kato K. Mapping and ablation of idiopathic ventricular ﬁbrillation from the Purkinje system. Heart Rhythm 2005; 2:646-649.
Carbucicchio C., Santamaria M., Trevisi N., Maccabelli G., Giraldi F., Fassini G., Riva S., Moltrasio M., Cireddu M., Veglia F., Della Bella P. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-deﬁbrillators: short- and long-term outcomes in a prospective single-center study. Circulation 2008; 117:462-469.
Kojodjojo P., Tokuda M., Bohnen M., Michaud G.F., Koplan B.A., Epstein L.M., Albert C.M., John R.M., Stevenson W.G., Tedrow U.B.. Electrocardiographic left ventricular scar burden predicts clinical outcomes following infarct-related ventricular tachycardia ablation. Heart Rhythm 2013; 10:1119-1124.
Della Bella P., Baratto F., Tsiachris D., Trevisi N., Vergara P., Bisceglia C, Petracca F., Carbucicchio C., Benussi S., Maisano F., Alﬁeri O., Pappalardo F., Zangrillo A., Maccabelli G. Management of ventricular tachycardia in the setting of a dedicated unit for the treatment of complex ventricular arrhythmias: long-term outcome after ablation. Circulation 2013; 127:1359-1368.
Connolly S.J., Dorian P., Roberts R.S., Gent M., Bailin S., Fain E.S., Thorpe K., Champagne J., Talajic M., Coutu B., Gronefeld G.C., Hohnloser S.H. Optimal Pharmacological Therapy in Cardioverter Deﬁbrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter deﬁbrillators: the OPTIC Study: a randomized trial. JAMA 2006; 295:165 - 171.
Calkins H., Epstein A., Packer D., Arria A.M., Hummel J., Gilligan D.M., Trusso J., Carlson M., Luceri R., Kopelman H., Wilber D., Wharton J.M., Stevenson W. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators Group. J Am Coil Cardiol 2000; 35: 1905-1914.
Stevenson W.G., Wilber D.J., Natale A., Jackman W.M., Marchlinski F.E., Talbert T., Gonzalez M.D., Worley S.J., Daoud E.G., Hwang C., Schuger C., Bump T.E., Jazayeri M., Tomassoni G.F., Kopelman H.A., Soejima K., Nakagawa H. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation 2008; 118:2773-2782.
Tanner H., Hindricks G., Volkmer M., Furniss S., Kuhlkamp V., Lacroix D., CDEC, Almendral J., Caponi D., Kuck K.H., Kottkamp H. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol 2010; 2.1:47- 53.
Visser C.A., Kan G., David G.K., Lie K.I., Durrer D. Two dimensional echocardiography in the diagnosis of left ventricular thrombus: a prospective study of 67 patients with anatomic validation. Chest 1983; 83:228–232.
Ezekowitz M.D., Wilson D.A., Smith E.O. et al. Comparison of Indium-111 platelet scintigraphy and two-dimensional echocardiography in the diagnosis of left ventricular thrombi. N Engl J Med 1982; 306:1509–1513.
Stratton J.R., Lighty G.W. Jr, Pearlman A.S., Ritchie J.L. Detection of left ventricular thrombus by two-dimensional echocardiography: sensitivity, speciﬁcity, and causes of uncertainty. Circulation 1982; 66:156–166.
Thanigaraj S., Schechtman K.B., Perez J.E. Improved echocardiographic delineation of left ventricular thrombus with the use of intravenous second-generation contrast image enhancement. J Am Soc Echocardiogr 1999; 12: 1022–1026.
Weinsaft J.W., Kim H.W., Shah D.J. et al. Detection of left ventricular thrombus by delayed- enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction. J Am Coll Cardiol 2008; 52: 148–157.
Weinsaft J.W., Kim R.J., Ross M. et al. Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. JACC Cardiovasc Imaging 2009; 2:969–979.
Siontis K.C., Kim H.M., Sharaf Dabbagh G. et al. Association of preprocedural cardiac magnetic resonance imaging with outcomes of ventricular tachycardia ablation in patients with idiopathic dilated cardiomyopathy. Heart Rhythm 2017; 14:1487–1493.
Zghaib T., Ipek E.G., Hansford R. et al. Standard ablation versus magnetic resonance imaging- guided ablation in the treatment of ventricular tachycardia. Circ Arrhythm Electrophysiol 2018; 11:e005973.
Andreu D., Penela D., Acosta J. et al. Cardiac magnetic resonance-aided scar dechanneling: inﬂuence on acute and long-term outcomes. Heart Rhythm 2017; 14:1121–1128.
Dickfeld T., Tian J., Ahmad G. et al. MRI-guided ventricular tachycardia ablation: integration of late gadolinium-enhanced 3D scar in patients with implantable cardioverter-deﬁbrillators. Circ Arrhythm Electrophysiol 2011; 4: 172–184.
Fernandez-Armenta J., Berruezo A., Andreu D. et al. Three-dimensional architecture of scar and conducting channels based on high resolution ceCMR: insights for ventricular tachycardia ablation. Circ Arrhythm Electrophysiol 2013; 6:528–537.
Gupta S., Desjardins B., Baman T. et al. Delayed-enhanced MR scar imaging and intraprocedural registration into an electroanatomical mapping system in post-infarction patients. JACC Cardiovasc Imaging 2012; 5:207–210.
Marra M.P., Leoni L., Bauce B. et al. Imaging study of ventricular scar in arrhythmogenic right ventricular cardiomyopathy: comparison of 3D standard electroanatomical voltage mapping and contrast-enhanced cardiac magnetic resonance. Circ Arrhythm Electrophysiol 2012; 5:91–100.
Nakahara S., Vaseghi M., Ramirez R.J. et al. Characterization of myocardial scars: electrophysiological imaging correlates in a porcine infarct model. Heart Rhythm 2011; 8:1060– 1067.
Ghannam M., Cochet H., Jais P. et al. Correlation between computer tomography- derived scar topography and critical ablation sites in postinfarction ventricular tachycardia. J Cardiovasc Electrophysiol 2018; 29:438–445.
Esposito A., Palmisano A., Antunes S. et al. Cardiac CT with delayed enhancement in the characterization of ventricular tachycardia structural substrate: relationship between CT- segmented scar and electro-anatomic mapping. JACC Cardiovasc Imaging 2016; 9:822–832.
Yamashita S., Sacher F., Mahida S. et al. Image integration to guide catheter ablation in scar- related ventricular tachycardia. J Cardiovasc Electrophysiol 2016; 27:699–708.
Komatsu Y., Cochet H., Jadidi A. et al. Regional myocardial wall thinning at multidetector computed tomography correlates to arrhythmogenic substrate in postinfarction ventricular tachycardia: assessment of structural and electrical substrate. Circ Arrhythm Electrophysiol 2013; 6:342–350.
Andreu D., Ortiz-Perez J.T., Boussy T. et al. Usefulness of contrast-enhanced cardiac magnetic resonance in identifying the ventricular arrhythmia substrate and the approach needed for ablation. Eur Heart J 2014; 35: 1316–1326.
Soto-Iglesias D., Acosta J., Penela D. et al. Image-based criteria to identify the presence of epicardial arrhythmogenic substrate in patients with transmural myocardial infarction. Heart Rhythm 2018; 15:814–821.
Reddy V.Y., Reynolds M.R., Neuzil P. et al. Prophylactic catheter ablation for the prevention of deﬁbrillator therapy. N Engl J Med 2007; 357: 2657–2665.
Kumar S., Baldinger S.H., Romero J. et al. Substrate-based ablation versus ablation guided by activation and entrainment mapping for ventricular tachycardia: a systematic review and meta- analysis. J Cardiovasc Electrophysiol 2016; 27:1437–1447.
Acosta J., Penela D., Andreu D. et al. Multielectrode vs. point-by-point mapping for ventricular tachycardia substrate ablation: a randomized study. Europace 2018; 20:512–519.
Berte B., Relan J., Sacher F. et al. Impact of electrode type on mapping of scar-related VT. J Cardiovasc Electrophysiol 2015; 26:1213–1223.
Yamashita S., Cochet H., Sacher F. et al. Impact of new technologies and approaches for post- myocardial infarction ventricular tachycardia ablation during long-term follow-up. Circ Arrhythm Electrophysiol 2016; 9:e003901.
Hutchinson M.D., Gerstenfeld E.P., Desjardins B. et al. Endocardial unipolar voltage mapping to detect epicardial ventricular tachycardia substrate in patients with nonischemic left ventricular cardiomyopathy. Circ Arrhythmia Electrophysiol 2011; 4:49–55.
Polin G.M., Haqqani H., Tzou W. et al. Endocardial unipolar voltage mapping to identify epicardial substrate in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm 2011; 8:76–83.
Chopra N., Tokuda M., Ng J. et al. Relation of the unipolar low-voltage penumbra surrounding the endocardial low-voltage scar to ventricular tachycardia circuit sites and ablation outcomes in ischemic cardiomyopathy. J Cardiovasc Electrophysiol 2014; 25:602–608.
Soto-Becerra R., Bazan V., Bautista W. et al. Ventricular tachycardia in the setting of Chagasic cardiomyopathy. Circ Arrhythm Electrophysiol 2017; 10: e004950.
Desjardins B., Yokokawa M., Good E. et al. Characteristics of intramural scar in patients with nonischemic cardiomyopathy and relation to intramural ventricular arrhythmias. Circ Arrhythm Electrophysiol 2013; 6:891–897.
Deyell M.W., Park K.M., Han Y., Frankel D.S., Dixit S., Cooper J.M., Hutchinson M.D., Lin D., Garcia F., Bala R., Riley M.P., Gerstenfeld E., Callans D.J., Marchlinski F.E. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm 2012; 9:1465 - 1472.
Barnan T.S., Lange D.C., IIg K.J., Gupta S.K., Liu T.Y., Alguire C., Armstrong W., Good E., Chugh A., Jongnarangsin K., Pelosi F.Jr., Crawford T., Ebinger M., Oral H., Morady F., Bogun F. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010; 7:865-869.
Ban J.E., Park H.C., Park J.S., Nagamoto Y., Choi J.I., Lim H.E., Park S.W., Kim Y.H. Electrocardiographic and electrophysiological characteristics of premature ventricular complexes associated with left ventricular dysfunction in patients without structural heart disease. Europace 2013; 5:735-41.
Schwartz P.J., Motolese M., Pollavini G. Prevention of sudden cardiac death after a ﬁrst myocardial infarction by pharmacologic or surgical antiadrenergic interventions. J Cardiovasc Electrophysiol. 1992; 3:2–16.
Vaseghi M., Gima J., Kanaan C. et al. Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: intermediate and long-term follow-up. Heart Rhythm. 2014; 11:360–6.
Ajijola O.A., Lellouche N., Bourke T. et al. Bilateral cardiac sympathetic denervation for the management of electrical storm. J Am Coll Cardiol. 2012; 59:91–2.
Vakil K., Taimeh Z., Sharma A. et al. Incidence, predictors, and temporal trends of sudden cardiac death after heart transplantation. Heart Rhythm. 2014; 11:1684–90.
Vaseghi M., Lellouche N., Ritter H. et al. Mode and mechanisms of death after orthotopic heart transplantation. Heart Rhythm. 2009; 6:503–9.
Tsai V.W., Cooper .J, Garan H. et al. The efﬁcacy of implantable cardioverter-deﬁbrillators in heart transplant recipients: results from a multicenter registry. Circ Heart Fail. 2009; 2:197–201.
McDowell D.L., Hauptman P.J. Implantable deﬁbrillators and cardiac resynchronization therapy in heart transplant recipients: results of a national survey. J Heart Lung Transplant. 2009; 28:847–50.
Neylon A., Canniffe C., Parlon B. et al. Implantable cardioverter-deﬁbrillators in a heart transplant population: A single-center experience. J Heart Lung Transplant. 2016; 35:682–4.
Ruwald A.C., Marcus F., Estes N.A. 3rd et al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy // Eur. HeartJ. – 2015. – Vol. 36. – P. 1735–1743.
Corrado D., Leoni L., Link M.S. et al. Implantable cardioverter-deﬁbrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia // Circulation. – 2003. – Vol. 108 – P. 3084–3091.
Marcus G.M., Glidden D.V., Polonsky B. et al. Multidisciplinary Study of Right Ventricular Dysplasia Investigators. Efﬁcacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry // J. Am. Coll. Cardiol. – 2009. – Vol. S4. – P. 609–615.
Wichter T., Borggrefe M., Haverkamp W. et al. Efﬁcacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia // Circulation. – 1992. – Vol. 86. – P. 29–37.
Edmond M. Cronin (Chair), Frank M. Bogun (Vice-Chair), Philippe Maury (EHRA Chair) et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias Europace (2019) 00, 1–147 doi:10.1093/europace/euz132.
Philips B., Madhavan S., James C. et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy // Circ. Arrhythm. Electrophysiol. – 2012. – Vol. 5. – N. 3 – P. 499–505.
Santangeli P., Zado E.S., Supple G.E., Haqqani H.M., Garcia F.C., Tschabrunn C.M., Callans D.J., Lin D., Dixit S., Hutchinson M.D., Riley M.P., Marchlinski F.E. Long-Term Outcome With Catheter Ablation of Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. – Circ Arrhythm Electrophysiol. 2015 Dec; 8(6):1413-21. doi: 10.1161/CIRCEP.115.003562. Epub 2015 Nov 6.
Berruezo A., Acosta J., Fernandez-Armenta J. et al. Safety, long-term outcomes and predictors of recurrence after ﬁrst-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy. Impact of arrhythmic substrate distribution pattern. A prospective multicentre study. -Europace 2017; 19:607–616.
Berruezo A., Fernandez-Armenta J., Mont L. et al. Combined endocardial and epicardial catheter ablation in arrhythmogenic right ventricular dysplasia incorporating scar dechanneling technique // Circ. Arrhythm. Electrophysiol. –2012. – Vol. 5. – P. 111–121.
Bai R., Di Biase L., Shivkumar K. et al. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation // Circ. Arrhythm. Electrophysiol. – 2011. – Vol. 4. – P. 478–485.
Roguin A., Bomma C.S., Nasir K. et al. Implantable cardioverterdeﬁbrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy // J. Am. Coil. Cardiol. – 2004. – Vol. 43. – P 1843–1852.
Bhonsale A., James C.A., Tichnell C. et al. Incidence and predictors of implantable cardioverter– deﬁbrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter–deﬁbrillator implantation for primary prevention // J. Am. Coil. Cardiol. – 2011. –Vol. 58. – P. 1485–1496.
Bhandari A.K., Shapiro W.A., Morady F., Shen E.N., Mason J., Scheinman M.M. Electrophysiologic testing in patients with the long QT syndrome. Circulation 1985; 71: 63-71.
Schwartz P.J., Priori S.G., Spazzolini C., Moss A.J., Vincent G.M., Napolitano C., Denjoy I., Guicheney P., Breithardt G., Keating M.T., Towbin J.A., Beggs A.H., Brink P., Wilde A.A., Toivonen L., Zareba W., Robinson J.L., Timothy K.W., Corﬁeld V., Wattanasirichaigoon D., Corbett C., Haverkamp W., Schulze-Bahr E., Lehmann M.H., Schwartz K., Coumel P., Bloise R. Genotype-phenotype correlation in the Iong-QT syndrome: gene-speciﬁc triggers for lifethreatening arrhythmias. Circulation 2001; 103:89-95.
Priori S.G., Napolitano C., Schwartz P.J., Grillo M., Bloise R., Ronchetti E., Moncalvo C., Tulipani C., Veia A., Bottelli G., Nastoli J. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004; 292: 1341 – 1344.
Keren A., Tzivoni D., Gavish D. et al. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation. 1981; 64:1167-74.
Schwartz P.J., Woosley R.L. Predicting the unpredictable: drug-induced QT prolongation nd torsades de pointes. J Am Coll Cardiol. 2016; 67:1639-50.
Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010; 62:760-81.
Mönnig G, Köbe J, Löher A, Eckardt L, Wedekind H, Scheld HH et al. Implantable cardioverter- deﬁbrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm 2005; 2(5): 497-504.
Schwartz P.J., Priori S.G., Cerrone M., Spazzolini C., Odero A., Napolitano C., Bloise R., De Ferrari G.M., Klersy C., Moss A.J., Zareba W., Robinson J.L., Hall W.J., Brink P.A., Toivonen L., Epstein A.E., Li C., Hu D. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QTsyndrome. Circulation 2004; 109:1826-1833.
Schwartz P.J., Priori S.G., Locati E.H., Napolitano C., Cantu F., Towbin J.A., Keating M.T., Hammoude H., Brown A.M., Chen L.S. Long QT syndrome patients with mutations of the SCNSA and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-speciﬁc therapy. Circulation 1995; 92:3381-3386.
Moss A.J., Windle J.R., Hall W.J., Zareba W., Robinson J.L., McNitt S., Severski P., Rosero S., Daubert J.P., Qi M., Cieciorka M., Manalan A.S. Safety and efﬁcacy of ﬂecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial Ann Noninvasive Electrocardiol 2005; 10:59-66.
Moss A.J., Zareba W., Schwarz K.Q., Rosero S., McNitt S., Robinson J.L. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 Iong-QT syndrome. J Cardiovasc Electrophysiol 2008; 19:1289-1293.
Priori S.G., Wilde A.A., Horie M., Cho Y., Behr E.R., Berut C., Btom N., Brugada J., Chiang C.E., Huikuri H., Kannankeril P., Krahn A., Leenhardt A., Moss A., Schwartz P.J., Shimizu W., Tomasetti G., Tracy C. Executive summary: HRS/ EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace 2013; 15: 1389-1406.
Giustetto C., Schimpf R., Mazzanti A., Scrocco C., Maury P., Anttonen O., Probst V., Blanc J.J., Sbragia P., Dalmasso P., Borggrefe M., Gaita F. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 2011; 58:587-595.
Gaita F., Giustetto C., Bianchi F., Schimpf R., Haissaguerre M., Calo L., Brugada R., Antzelevitch C., Borggrefe M., Wolpert C. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 2004; 43:1494-1499.
Maury P., Hocini M., Haissaguerre M. Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options. Indian Pacing Electrophysiol J 2005; 5:25-34.
Marquez M.F., Bonny A., Hemandez-Castillo E., De Sisti A., Gomez-Flores J., Nava S., Hidden- Lucet F., Iturralde P., Cardenas M., Toner J. Long-term efﬁcacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-deﬁbrillator: a case series and literature review. Heart Rhythm 2012; 9:1995-2000.
Brugada J., Brugada R., Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003; 108:3092-3096.
Haissaguerre M., Extramiana F., Hocini M., Cauchemez B., Jais P., Cabrera J.A., Farre J., Leenhardt A., Sanders P., Scavee C., Hsu L.F., Weerasooriya R., Shah D.C., Frank R., Maury P., Delay M., Garrigue S., Clementy J. Mapping and ablation of ventricular ﬁbrillation associated with Long-QT and Brugada syndromes. Circulation 2003; 108: 925- 928.
Nademanee K., Veerakul G., Chandanamattha P., Chaothawee L., Ariyachaipanich A., Jirasirirojanakorn K., Likittanasombat K., Bhuripanyo K., Ngarmukos T. Prevention of ventricular ﬁbrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outﬂow tract epicardium. Circulation 2011; 123:1270-1279.
Leenhardt A., Lucet V., Denjoy I., Grau F., Ngoc D.D., Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995; 71:1512- 1519.
Guicheney P., Lunardi J., Leenhardt A. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricutar tachycardia. Circulation 2009; 119:2426-2434.
Watanabe H., Chopra N., Laver D., Hwang H.S., Davies S.S., Roach D.E., Duff H.J., Roden D.M., Wilde A.A., Knollmann B.C. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Meal 2009; 15: 380-383.
Otde Nordkamp L.R., Driessen A.H., Odero A., Biota N.A., Koolbergen D.R., Schwartz P.J., Wilde A.A. Left cardiac sympathetic denervation in the Netherlands for the treatment of inherited arrhythmia syndromes. Neth Heart J 2014; 22: 160-166.
Hofferberth S.C., Cecchin F., Loberman D., Fynn-Thompson F. Left thoracoscopic sympathectomy for cardiac denervation in patients with life-threatening ventricutar arrhythmias. J Thorac Cardiovasc Surg 2014; 147:404-409.
Beaufort-Krot G.C., Dijkstra S.S., Bink-Boelkens M.T. Natural history of ventricutar premature contractions in children with a structurally normal heart: does origin matter? Europace 2008; 10:998-1003.
Pfammatter J.P., Paul T. Idiopathic ventricular tachycardia in infancy and childhood: a multicenter study on clinical proﬁle and outcome. Working Group on Dysrhythmias and Electrophysiology of the Association for European Pediatric Cardiology. J Am Coil Cardiol. 1999; 33:2067-2072.
Wang S., Zhu W., Hamilton R.M., Kirsh J.A., Stephenson E.A., Gross G.J. Diagnosis speciﬁc characteristics of ventricutar tachycardia in children with structurally normat hearts. Heart Rhythm 2010; 7:1725-1731.
Collins K.K., Schaffer M.S., Liberman L., Saarel E., Knecht M., Tanet R.E., Bradley D., Dubin A.M., Paul T., Salerno J., Bar-Cohen Y., Sreeram N., Sanatani S., Law I.H., Btaufox A., Batra A., Mottedo J.M., van Hare G.F., Reed J., Ro P.S., Kugter J., Anderson C., Triedman J.K. Fascicular and nonfascicular left ventricular tachycaralias in the young: an international multicenter study. J Cardiovasc Electrophysiol 2013; 2.4:640-648.
Schneider H.E., Kriebel T., Jung K., Gravenhorst V.D., Paul T. Catheter ablation of idiopathic left and right ventricular tachycardias in the pediatric population using noncontact mapping. Heart Rhythm 2010; 7:731-739.
Желудочковые аритмии / М.А. Школьникова, В.В. Березницкая // Клинические рекомендации по детской кардиологии и ревматологии / под ред. М.А. Школьниковой, Е.И. Алексеевой. – М., 2011. – Гл. 5. – С. 133–159.
Pharmacological and non–pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC - Arrhythmia Working Group joint consensus statement / J. Brugada, N. Blom, G. Sarquella-Brugada et al. // Europace. – 2012. – Vol. 15, N 9. – P. 1337–1382.
Lapage M.J., Bradley D.J., Dick M. 2nd. Verapamil in infants: an exaggerated fear? Pediatr Cardiol 2013; 34:1532-1534.
Blaufox A.D., Felix G.L., Saul J.P. Radiofrequency catheter ablation in infants </=18 months old: when is it done and how do they fare?: short-term data from the pediatric ablation registry. Circulation 2001; 104:2803-280.
Gallego P., Gonzalez A.E., Sanchez-Recalde A., Peinado R., Polo L., Gomez-Rubin C., Lopez- Sendon J.L., Oliver J.M. Incidence and predictors of sudden cardiac arrest in adults with congenital heart defects repaired before adult life. Am J Cardiol 2012; 110:109 – 117.
Khairy P., Landzberg M.J., Gatzoulis M.A., Lucron H., Lambert J., Marcon F., Alexander M.E., Walsh E.P. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation 2004; 109:1994–2000.
Koyak Z., Harris L., de Groot J.R., Silversides C.K., Oechslin E.N., Bouma B.J., Budts W., Zwinderman A.H., Van Gelder I.C., Mulder B.J. Sudden cardiac death in adult congenital heart disease. Circulation 2012; 126:1944 – 1954.
PACES/HRS expert consensus statement on the evaluation and management of ventricular arrhythmias in the child with a structurally normal heart / J.E. Crosson, D.J. Callans, D.J. Bradleyetal. // HeartRhythm. – 2014. – Vol. 11, N 9. – P. e55–e78.
Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств / Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции; разраб. А. Ш. Ревишвили. – 3-е изд., доп. и перераб. – М. : МАКС-Пресс, 2013. – 595 с. 16.
Caforio A.L., Pankuweit S., Arbustini E. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases // Eur. Heart J. – 2013. – Vol. 34. – P. 2636–2648.
Aoyama N., Izumi T., Hiramori K. et al. National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientiﬁc committee) // Circ. J. – 2002. – Vol. 66 – P. 133–144.
Liberman L., Anderson B., Silver E.S. et al. Incidence and characteristics of arrhythmias in pediatric patients with myocarditis: a multicenter study // J. Am. Coil. Cardiol. – 2014. – Vol. 63. – P. A483.
Kindermann I., Kindermann H., Kandolf R. et al. Predictors of outcome in patients with suspected myocardills // Circulation. – 2008. – Vol. 118. – P. 639–648.
Yancy C.W., Jessup M., Bozkurt B. et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines // Orculation. – 2013. – Vol. 128. – P. 1810–1852.
Prochnau D., Surber R., Kuehnert H. et al. Successful use of a wearable cardioverter-deﬁbrillator in myocarditis with normal ejection fraction // Clin. Res. Cardiol. – 2010. – Vol. 99. – P. 129–131.
Chung H.K. The role of the wearable cardioverter deﬁbrillator in clinical practice // Cardiol. Clin. – 2014. – Vol. 32. – P. 253–270.
Kandolin R., Lehtonen J., Salmenkivi K. et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression // Grc. Heart Fail. – 2013. – Vol. 6. – P. 15–22.
Schumm J., Greulich S., Wagner A. et al. Cardiovascular magnetic resonance risk stratiﬁcation in patients with clinically suspected myocarditis // J. Cardiovasc. Magn. Reson. – 2014. – Vol. 16. – P. 14.
JCS Joint Working Group. Guidelines for diagnosis and treatment of myocarditis (JCS 2009): digest version // Circ. J. – 2011. – Vol. 75. – P. 734–743.
Wever E.F., Robles de Medina E.O. Sudden death in patients without structural heart disease // J. Am. Coil. Cardiol. – 2004. – Vol. 43. – P. 1137–1144.
Plazzone P., Tsiachris D., della Bella P. Epicardial management of myocarditisrelated ventricular tachycardia // Eur. Heart J. – 2013. – Vol. 34. – P. 244.
Wallace S.M., Walton B.I., Kharbanda R.K. et al. Mortality from infective endocarditis: clinical predictors of outcome // Heart. – 2002. – Vol. 88. – P. 53–60.
Aranki S.F., Santini F., Adams D.H. et al. Aortic valve endocarditis. Determinants of early survival and late morbidity // Circulation. – 1994. – Vol. 90. – P. 11175–11182.
Yang F., Shah B., Iwai S. et al. ICD implantation and arrhythmia-free survival in patients with depressed LV function following surgery for valvular heart disease // Pacing Clin. Electrophysiol. – 2008. – Vol. 31. – P. 1419–1424.
Valles A.G., Khawaja F.J., Gersh B.J. et al. Implantable cardioverter deﬁbrillators in patients with valvular cardiomyopathy // J. Cardiovasc. Electrophysiol. – 2012. – Vol. 2. – N. 3. – P. 1326–1332.
Rosenheck S., Weiss A., Sharon Z. Therapy success and survival in patients with valvular heart disease and implantable cardioverter deﬁbrillator // Int. J. Cardiol. – 2010. – Vol. 144. – P. 103– 104.
Johnson L.L., Sciacca R.R., Ellis K. et al. Reduced left ventricular myocardial blood ﬂow per unit mass in aortic stenosis // Circulation. – 1978. – Vol. 57. – P. 582–590.
Martinez-Rubio A., Schwammenthal Y., Schwammenthal E. et al. Patients with valvular heart disease presenting with sustained ventricular tachyarrhythmias or syncope: results of programmed ventricular stimulation and long-term followup // Circulation. – 1997. – Vol. 96. – P. 500–508.
Narasimhan C., Jazayeri M.R., Sra J. et al. Ventricular tachycardia in valvular heart disease: facilitation of sustained bundle-branch reentry by valve surgery // Circulation. – 1997. – Vol. 96. – P. 4307–4313.
Groh W.J., Groh M.R., Saha C. et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008; 358:2688-2697.
Wahbi K., Meune C., Porcher R. et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA 2012; 307:1292-1301.
Laurent V., Petlieux S., Corcia P. et al. Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices. Int J Cardiol 2011; 150:54-58.
Meune C., Van Berto J.H., Anselme F. et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med 2006; 354:209-210.
Pegitz-Zagrosek V., Btomstrom Lundqvist C., Borghi C. et al. ЕОК Committee for Practice Guidelines. ЕОК Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ЕОК). Eur Heart J 2011; 32:3147-3197.
Rashba E.J., Zareba W., Moss A.J., Halt W.J., Robinson J., Locati E.H., Schwartz P.J., Andrews M. Inﬂuence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation 1998; 97: 451-456.
Siu S.C., Sermer M., Cotman J.M. et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104: 515--521.
Drenthen W., Pieper P.G., Roos-Hessetink J.W. et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 47:2303-2311.
Poos-Hessetink J.W., Puys T.P., Stein J.I. et al. Outcome of pregnancy in patients with structural or isсhemic heart disease: results of a registry of the European Society of Cardiology. Eur HeartJ 2013; 34: 657-665.
Rodriguez-Manero M., Casado-Arroyo P., Sarkozy A. et al. The clinical signiﬁcance of pregnancy in Brugada syndrome, ﬂev Esp Cardiol (Engl Ed) 2014; 67:176-180.
Benito B., Berruezo A. Brugada syndrome and pregnancy: delving into the role of sex hormones in ion channelopathies. Rev Esp Cardiol (Engl Ed) 2014; 67:165-167.
Silversides C.K., Harris L., Haberer K., Sermer M., Colman J.M., Siu S.C. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol 2006; 97:1206-1212.
Sharif-Kazemi M.B., Ernkanjoo Z., Tavoosi A. et al. Electrical storm in Brugada syndrome during pregnancy. Pacing Clin Electrophysiol 2011; 34:el 8-e21.
Sliwa K., Fett J., Elkayam U. Peripartum cardiomyopathy. Lancet 2006; 368: 687-69.
Gunderson E.P., Croen L.A., Chiang V., Yoshida C.K., Watton D., Go A.S. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol 2011; 118:583-591.
Gowda R.M., Khan I.A., Mehta N.J. et al. Cardiac arrhythmias in pregnancy: clinical and therapeutic considerations. Int J Cardiol 2003; 88:129-133.
Habli M., O"Brien T., Nowack E., Khoury S., Barton J.R., Sibai B. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am J Obstet Gynecol 2008; 199:415.e1- 415.eS.
Simantirakis E.N., Schiza S.I., Marketou M.E. et al. Severe bradyarrhythmias in patients with sleepapnea: the effect of continuous positive airway pressure treatment: a longterm evaluation using an insertable loop recorder. Eur Heart J 2004; 25: 1070-1076.
Gami A.S., Otson E.J., Shen W.K. et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. J Am Coil Cardiol 2013; 62:610-616.
Marshall N.S., Wong K.K., Liu P.Y. et al. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008; 31:1079-1085.
Young T., Finn L., Peppard P.E. et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008; 31:1071-1078.
Guitleminault C., Connolly S.J, Winkle R.A. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. Am J Cardiol 1983; S2:490-494.
Becker H.F., Koehter U., Stammnitz A., Peter J.H. Heart block in patients with sleep apnea. Thorax 1998; S3(Suppl 3):S29-S32.
Grimm W., Hoffmann J., Menz V. et al. Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea. Am J Cardiol 1996; 77:1310-1314.
Mehra R., Benjamin E.J., Shahar E. , Gotttieb D.J., Nawabit R., Kirchner H.L., Sahadevan J., Redtine S. et al. Association of nocturnal arrhythmias with sleep-disordered breathing: the Sleep Heart Health Study. Am J Respir Crit Care Med 2006; 173:910-916.
Hoffstein V., Mateika S. Cardiac arrhythmias, snoring, and sleep apnea. Chest 1994; 106:466- 471.
Tilkian A.G., Guilleminault C., Schroeder J.S., Lehrman K.L., Simmons F.B., Dement W.C. Sleep- induced apnea syndrome. Prevalence of cardiac arrhythmias and their reversal after tracheostomy. Am J Med 1977; 63:348-358.
Harbison J., O"Reilly P., McNicholas W.T. Cardiac rhythm disturbances in the obstructive sleep apnea syndrome: effects of nasal continuous positive airway pressure therapy. Chest 2000; 118:591-595.
Grimm W., Koehler U., Fus E. et al. Outcome of patients with sleep apnea-associated severe bradyarrhythmias after continuous positive airway pressure therapy. Am J Cardiol 2000; 86:688- 692.
Koehter U., Fus E., Grimm W. et al. Heart block in patients with obstructive sleep apnea: pathogenetic factors and effects of treatment. Eur RespirJ 1998; 11:434-439.
Stegman S.S., Burroughs J.M., Henthorn R.W. Asymptomatic bradyarrhythmias as a marker for sleep apnea: appropriate recognition and treatment may reduce the need for pacemaker therapy. Pacing Clin Electrophysiol 1996; 19:899- 904.
Strotto P.J.Jr, Soose R.J., Maurer J.T. et al. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med 2014; 370: 139-149.
Elliott P.M., Gimeno J.R., Thaman R., Shah J., Ward D., Dickie S., Tome Esteban M.T., McKenna W.J. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006; 92:785–791.
O’Mahony C., Jichi F., Pavlou M., Monserrat L., Anastasakis A., Rapezzi C., Biagini E., Gimeno J.R., Limongelli G., McKenna W.J., Omar R.Z., Elliott P.M. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014; 35:2010–2020.
Pelliccia A., Fagard R., Bjornstad H.H., Anastassakis A., Arbustini E., Assanelli D., Bifﬁ A., Borjesson M., Carre F., Corrado D., Delise P., Dorwarth U., Hirth A., Heidbuchel H., Hoffmann E., Mellwig K.P., Panhuyzen-Goedkoop N., Pisani A., Solberg E.E., van-Buuren F., Vanhees L., Blomstrom-Lundqvist C., Deligiannis A., Dugmore D., Glikson M., Hoff P.I., Hoffmann A., Horstkotte D., Nordrehaug J.E., Oudhof J., McKenna W.J., Penco M., Priori S., Reybrouck T., Senden J., Spataro A., Thiene G. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26:1422–1445.
O’Mahony C., Tome-Esteban M., Lambiase P.D., Pantazis A., Dickie S., McKenna W.J., Elliott P.M. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratiﬁcation and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart 2013; 99:534–541.
O’Mahony C., Lambiase P.D., Quarta G., Cardona M., Calcagnino M., Tsovolas K., Al-Shaikh S., Rahman S.M., Arnous S., Jones S., McKenna W., Elliott P. The long-term survival and the risks and beneﬁts of implantable cardioverter deﬁbrillators in patients with hypertrophic cardiomyopathy. Heart 2012; 98:116–125.
Elliott P.M., Sharma S., Varnava A., Poloniecki J., Rowland E., McKenna W.J. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33:1596–1601.
Cecchi F., Maron B.J., Epstein S.E.. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989; 13:1283– 1288.
Maron B.J., Spirito P., Shen W.K., Haas T.S., Formisano F., Link M.S., Epstein A.E., Almquist A.K., Daubert J.P., Lawrenz T., Boriani G., Estes N.A. 3rd, Favale S., Piccininno M., Winters S.L., Santini M., Betocchi S., Arribas F., Sherrid M.V., Buja G., Semsarian C., Bruzzi P. Implantable cardioverter-deﬁbrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298:405–412.
Syska P., Przybylski A., Chojnowska L., Lewandowski M., Sterlinski M., Maciag A., Gepner K., Pytkowski M., Kowalik I., Maczynska-Mazuruk R., Ruzyllo W., Szwed H. Implantable cardioverter-deﬁbrillator in patients with hypertrophic cardiomyopathy: efﬁcacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol 2010; 21:883– 889.
Клинические рекомендации «Желудочковые аритмии» МЗ РФ, ФГБУ «ННПЦССХ им. А.Н. Бакулева» МЗ РФ Центр хирургической и интервенционной аритмологии. Москва 2017 г. – 38 с.
Yoshinaga M., Ushinohama H., Sato S., Tauchi N., Horigome H., Takahashi H., Sumitomo N., Kucho Y., Shiraishi H., Nomura Y., Shimizu W., Nagashima M. Etectrocardiographic screening of 1-month-old infants for identifying prolonged QT intervals. Circ Arrhythm Electrophysiol 2013; 6:932-938.
Narain R., Dhutia H., Merghani A. et al. Preventing sudden cardiac death in the young: results from a population-based screening program in the UK // European Journal of Preventive Cardiology. – 2014. – Vol. 21. – suppl. – S1–S6.
Kattman J.R., Thompson P.D., Lantos J. et al. Screening for sudden cardiac death in the young: report from a national heart, lung, and brood institute working group // Circulation. – 2011. – Vol. 123. – P. 1911–1918.
Приказ Министерства здравоохранения Российской Федерации от 26.10.2017 № 869н «Об утверждении порядка проведения диспансеризации определенных групп взрослого населения».
Приложение № 1 к приказу Министерства здравоохранения Российской Федерации от 10.08.2017 № 514н «О порядке прохождения несовершеннолетними медицинских осмотров, в том числе при поступлении в образовательные учреждения и в период обучения в них».
Школьникова М.А., Харлап М.С., Ильдарова Р.А. Генетически детерминированные нарушения ритма сердца // Российский кардиологический журнал. – 2011. – № 1 (87). – С. 8–25.
Школьникова М.А. Первичные электрические заболевания сердца как причина внезапной смерти // Доктор.ru. – 2008. – Т. 3. – С. 25–32.
Charron P., Arad M., Arbustini E. et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardiat Diseases // Eur. Heart J. – 2010. – Vol. 31. – P. 2715–2726.
Christiaans I., Birnie E., Bonsel G.J. et al. Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy // Eur. J. Hum Genet. – 2008. – Vol. 16. – P. 1201–1207.
Ormondroyd E., Oates S., Parker I. et al. Pre-symptomatic genetic testing for inherited cardiac conditions: a qualitative exploration of psychosocial and ethical implications // Eur. J. Hum. Genet. – 2014. – Vol. 22. – P. 88–93.
Ingles J., Yeates L., Hunt L. et al. Health status of cardiac genetic disease patients and their at- risk retatives // Int. J. Cardiol. – 2013. – Vol. 165. – P. 448–453.
Battista R.N., Blancquaert I., Laberge A.M, et al. Genetics in health care: an overview of current and emerging models // Public Health Genomics. – 2012. – Vol. 15. – P. 34–45.
Ingles J., Lind J.M., Phongsavan P., Semsarian C. Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy // Genet. Meal. – 2008. – Vol. 10. – P. 117–120.
Christiaans I., van Langen I.M., Birnie E. et al. Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study // Am. J. Med. Genet. A. – 2009. – Vol. 149A. – P. 602–612.
McGorrian C., Constant O., Harper N. et al. Family–based cardiac screening in relatives of victims of sudden arrhythmic death syndrome // Europace. – 2013. – Vol. 15. – P. 1050–1058.
Sherazi Saadia,, Zareba Wojciech, Daubert James P., McNitt Scott, Shah Abrar H., Aktas Mehmet K., Block Robert C.. Physicians’ Knowledge and Attitudes Regarding Implantable Cardioverter- Deﬁbrillators. Cardiol J. 2010; 17(3): 267–273.
Charles C., Gafni A., Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997; 44:681–92.
Quill T.E, Brody H. Physician recommendations and patient autonomy: ﬁnding a balance between physician power and patient choice. Ann Intern Med. 1996; 125:763–9.
Lewis K.B., Stacey D., Matlock D.D. Making decisions about implantable cardioverter- deﬁbrillators from implantation to end of life: an integrative review of patients’ perspectives. Patient. 2014; 7: 243–60.
Stewart G.C., Weintraub J.R., Pratibhu P.P. etal. Patient expectations from implantable deﬁbrillators to prevent death in heart failure. J Card Fail. 2010; 16:106–13.
Hauptman P.J., Chibnall J.T., Guild C. et al. Patient perceptions, physician communication, and the implantable cardioverter-deﬁbrillator. JAMA Intern Med. 2013; 173:571–7.
Ottenberg A.L., Mueller P.S., Topazian R.J. et al. ”It’s not broke, so let’s not try to ﬁx it”: why patients decline a cardiovascular implantable electronic device. Pacing Clin Electrophysiol. 2014; 37:1306–14.
Yuhas J., Mattocks K., Gravelin L. et al. Patients’ attitudes and perceptions of implantable cardioverter-deﬁbrillators: potential barriers to appropriate primary prophylaxis. Pacing Clin Electrophysiol. 2012; 35:1179–87.
St John Sutton M., Pfeffer M.A., Plappert T., Rouleau J.L., Moye L.A., Dagenais G.R., Lamas G.A., Klein M., Sussex B., Goldman S. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994; 89:68-75.
Adler A., Van der Werf C., Postema P.G., Rosso R., Bhuiyan Z.A., Kalman J.M., Vohra J.K., Guevara-Valdivia M.E., Marquez M.F., Halkin A., Benhorin J., Antzelevitch C., Wilde A., Viskin S. The phenomenon of “QT stunning”: The abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm 2012; 9:901–908.
Комолятова В.Н., Макаров Л.М., Киселева И.И., Беспорточный Д.А., Дмитриева А.В., Балыкова Л.А., Паршина Т.С. Изменение интервала QT в ортостазе – новый диагностический маркер синдрома удлинённого интервала QT. Медицинский алфавит № 22 / 2019, том № 2.с.18-21.
Schwartz P.J., Crotti L. QTc Behavior During Exercise and Genetic Testing for the Long-QT Syndrome. Circulation 2011, 124:2181-2184.
Niwano S, Wakisaka Y, Niwano H, et al. Prognostic signiﬁcance of frequent premature ventricular contractions originating from the ventricular outﬂow tract in patients with normal left ventricular function. Heart 2009; 95: 1230 –1237
Lee V, Hemingway H, Harb R, Crake T, Lambiase P. The prognostic signiﬁcance of premature ventricular complexes in adults without clinically apparent heart disease: a meta-analysis and systematic review. Heart 2012; 98: 1290–1298
Kovoor, P., Love, A., Hall, J., Kruit, R., Sadick, N., Ho, D., … Ross, D. L. (2005). Randomized double-blind trial of sotalol versus lignocaine in out-of-hospital refractory cardiac arrest due to ventricular tachyarrhythmia. Internal Medicine Journal, 35(9), 518–525. doi:10.1111/j.1445- 5994.2005.00896.x
Pokorney, S. D., Miller, A. L., Chen, A. Y., Thomas, L., Fonarow, G. C., de Lemos, J. A., … Wang, T. Y. (2015). Implantable Cardioverter-Deﬁbrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. JAMA, 313(24), 2433. doi:10.1001/jama.2015.6409
Takemoto, M., Yoshimura, H., Ohba, Y., Matsumoto, Y., Yamamoto, U., Mohri, M., … Origuchi, H. (2005). Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outﬂow tract improves left ventricular dilation and clinical status in patients without structural heart disease. Journal of the American College of Cardiology, 45(8), 1259– 1265. doi:10.1016/j.jacc.2004.12.073
Santangeli P, Marchlinski FE, Zado ES, et al. Percutaneous epicardial ablation of ventricular arrhythmias arising from the left ventricular summit: outcomes and electrocardiogram correlates of success. Circ Arrhythm Electrophysiol 2015;8:337–343
Rillig, A., Meyerfeldt, U., Birkemeyer, R., Treusch, F., Kunze, M., Brasch, M., & Jung, W. (2008). Catheter ablation within the sinus of Valsalva—A safe and effective approach for treatment of atrial and ventricular tachycardias. Heart Rhythm, 5(9), 1265–1272. doi:10.1016/j.hrthm.2008.06.010
Jankowska, H., Dorniak, K., Hellmann, M., Dubaniewicz, A., & Dudziak, M. (2020). Arguable ICD placement in a sarcoidosis patient with extensive cardiac involvement. Archives of Medical Science, 16(3), 707–708. doi:10.5114/aoms.2019.86708
Cice G, Tagliamonte E, Ferrara L, Iacono A. Efﬁcacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study European Heart Journal; 21(15):1259–1264. doi:10.1053/euhj.1999.1984
McMurray J, Køber L, Robertson M, Dargie H, Colucci W, Lopez-Sendon J, Remme W, Sharpe DN, Ford I. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005;45(4):525-30. doi: 10.1016/j.jacc.2004.09.076
Ruwald AC, Gislason GH, Vinther M, Johansen JB, Nielsen JC, Philbert BT, Torp-Pedersen C, Riahi S, Jøns C. Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter- deﬁbrillator recipients: a Danish nationwide cohort study. EP Europace 2018; 20(FI2):f217–f224. doi:10.1093/europace/euy077
Luria HM, Adelson EI, Miller AJ. Acute and Chronic Effects of an Adrenergic Beta-Receptor Blocking Agent (Propranolol) in Treatment of Cardiac Arrhythmia. Circulation 1966; 34(5):767- 773. doi:10.1161/01.CIR.34.5.767
Mauritson DR, Winniford MD, Walker WS, RudeE RE, Cary JR, Hillis LD. Oral Verapamil for Paroxysmal Supraventricular Tachycardia. Annals of Internal Medicine 1982 96:4, 409-412.
Gill JS, Ward DE, Camm AJ. Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia. Pacing Clin Electrophysiol 1992;15(11 Pt 2):2122-6. doi: 10.1111/j.1540-8159.1992.tb03033.x
Yeh SJ, Kou HC, Lin FC, Hung JS, Wu D. Effects of oral diltiazem in paroxysmal supraventricular tachycardia. Am J Cardiol 1983;52(3):271-278. doi:10.1016/0002-9149(83)90121-2
Buckley MM, Grant SM, Goa KL et al. Diltiazem. A Reappraisal of its Pharmacological Properties and Therapeutic Use. Drugs 1990; 39:757–806. doi:10.2165/00003495-199039050-00009
Yeh SJ, Wen MS, Wang CC, Lin FC, Wu D. Adenosine-sensitive ventricular tachycardia from the anterobasal left ventricle. J Am Coll Cardiol 1997;30(5):1339-1345. DOI: 10.1016/s0735- 1097(97)00291-x
Avanzas Pablo, Arroyo-Espliguero Ramón, Cosín-Sales Juan, Quiles Juan, Zouridakis Emmanouil, Kaski Juan Carlos. Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis. 2004 Jul;175(1):151-7. doi: 10.1016/j.atherosclerosis.2004.03.013.
Morici Nuccia, Cantoni Silvia, Soriano Francesco, Viola Giovanna, De Stefano Valerio, Veas Nicolas, Oreglia Jacopo A, Esposito Giuseppe, Sacco Alice, Savonitto Stefano. Relevance of complete blood count parameters in the assessment of acute coronary syndromes: a combined hematological and cardiological perspective. G Ital Cardiol (Rome). 2019 Dec;20(12):694-705. doi: 10.1714/3271.32379.
Núñez J, Miñana G, Bodí V, Núñez E, Sanchis J, Husser O, Llàcer A. Low lymphocyte count and cardiovascular diseases. Curr Med Chem. . 2011;18(21):3226-33. doi: 10.2174/092986711796391633.
Suh Sunghwan, Cho Young Rak, Park Mi Kyoung, Kim Duk Kyu, Cho Nam H, Lee Moon-Kyu. Relationship between serum bilirubin levels and cardiovascular disease. PLoS One. . 2018 Feb 15;13(2):e0193041. doi: 10.1371/journal.pone.0193041. eCollection 2018.
Sibilitz Kirstine L, Benn Marianne, Nordestgaard Børge G. Creatinine, eGFR and association with myocardial infarction, ischemic heart disease and early death in the general population. Atherosclerosis. 2014 Nov;237(1):67-75. doi: 10.1016/j.atherosclerosis.2014.08.040. Epub 2014 Sep 3.
Zhang Qiu-Li, Brenner Hermann, Koenig Wolfgang, Rothenbacher Dietrich. Prognostic value of chronic kidney disease in patients with coronary heart disease: role of estimating equations. Atherosclerosis. 2010 Jul;211(1):342-7. doi: 10.1016/j.atherosclerosis.2010.02.028. Epub 2010 Mar 1.
Dobre Daniela, Rossignol Patrick, Metra Marco, Zannad Faiez. Can we prevent or treat renal dysfunction in chronic heart failure? Heart Fail Rev. 2012 Mar;17(2):283-90. doi: 10.1007/s10741-011-9264-0.
Alexander C M, Landsman P B, Teutsch S M. Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol. 2000 Nov 1;86(9):897-902. doi: 10.1016/s0002-9149(00)01118-8.
Kadowaki S, Okamura T, Hozawa A, Kadowaki T, Kadota A, Murakami Y, Nakamura K, Saitoh S, Nakamura Y, Hayakawa T, Kita Y, Okayama A, Ueshima H, NIPPON DATA Research Group. Relationship of elevated casual blood glucose level with coronary heart disease, cardiovascular disease and all-cause mortality in a representative sample of the Japanese population. NIPPON DATA80. Diabetologia. 2008 Apr;51(4):575-82. doi: 10.1007/s00125-007-0915-6. Epub 2008 Jan 16.
Nishimura M, Nakayama K, Ishikawa Y. Cardiac arrhythmias caused by electrolyte imbalance. Nihon Rinsho. 1996 Aug;54(8):2207-12.
Pilarczyk Kevin, Carstens Henning, Heckmann Jens, Canbay Ali, Koch Achim, Pizanis Nikolaus, Jakob Heinz, Kamler Markus. The aspartate transaminase/alanine transaminase (DeRitis) ratio predicts mid-term mortality and renal and respiratory dysfunction after left ventricular assist device implantation. Eur J Cardiothorac Surg. 2017 Oct 1;52(4):781-788. doi: 10.1093/ejcts/ezx247.
Narita Keisuke, Ureshino Hiroshi, Hashimoto Shigemasa. Sustained ventricular tachycardia caused by subacute thyroiditis. Intern Med J. 2018 Sep;48(9):1160-1162. doi: 10.1111/imj.14018.
Tsai I-Hsun, Su Yu-Jang. Thyrotoxic periodic paralysis with ventricular tachycardia. J Electrocardiol. May-Jun 2019;54:93-95. doi: 10.1016/j.jelectrocard.2019.04.001. Epub 2019 Apr 4.
Middeldorp Melissa E Elliott , Adrian D, Gallagher Celine, Linz Dominik, Hendriks Jeroen M L, Mahajan Rajiv, Lau Dennis H, Sanders Prashanthan. Late-onset thyrotoxicosis after the cessation of amiodarone. Indian Pacing Electrophysiol J. 2020 Aug 1;S0972-6292(20)30086-3. doi: 10.1016/j.ipej.2020.07.006. Online ahead of print.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница